Control of Inflammation Using Drug Delivery Strategies in in vitro Models by Wardwell, Patricia R
Syracuse University 
SURFACE 
Dissertations - ALL SURFACE 
June 2015 
Control of Inflammation Using Drug Delivery Strategies in in vitro 
Models 
Patricia R. Wardwell 
Syracuse University 
Follow this and additional works at: https://surface.syr.edu/etd 
 Part of the Engineering Commons 
Recommended Citation 
Wardwell, Patricia R., "Control of Inflammation Using Drug Delivery Strategies in in vitro Models" (2015). 
Dissertations - ALL. 260. 
https://surface.syr.edu/etd/260 
This Dissertation is brought to you for free and open access by the SURFACE at SURFACE. It has been accepted for 
inclusion in Dissertations - ALL by an authorized administrator of SURFACE. For more information, please contact 
surface@syr.edu. 
Abstract 
Regulation of inflammation is a crucial component of the immune system in response to 
injury and infection. In otherwise healthy individuals, an initial acute inflammatory response will 
subside once the injury or infection is eradicated. However, in certain disease states including 
autoimmune disease and persistent infection, miscommunication between cells of the immune 
system leads to a chronic inflammatory response, contributing to disease pathology and 
exacerbating symptoms. A major regulator of inflammation communication at the cellular level 
is transcription factor (TF) NF-κB. Under normal conditions, NF-κB is bound to an inhibitor in 
the cytoplasm. In a chronic disease state, NF-κB is overactive and found in the unbound form, 
resulting in increased production of inflammatory signals.  
 Transcription factor decoys (TFD) are small nucleic acid sequences (~20 base pairs) that 
mimic the binding site for the TF on the native DNA, but do not encode for any proteins. By 
binding to the TF in the cytoplasm, TFD have potential to limit excessive immune signaling and 
inflammatory protein production. Unfortunately, clinical success of TFD has been hampered by a 
lack of an effective delivery method. Lack of stability and ease of degradation of the TFD 
require a protective carrier for delivery; however many synthetic carrier systems induce toxicity 
or an enhanced inflammatory response. In disease states characterized by excessive 
inflammation, treatment-induced toxicity or immune response is highly undesirable.  
 The Bader lab has previously reported a nanoparticle carrier system based on natural 
polysaccharides, designed specifically for the treatment of rheumatoid arthritis. The materials 
used in this system have properties that can be exploited for the additional application of DNA 
delivery. This thesis will detail the adaptation of polysialic acid-N-trimethyl chitosan 
nanoparticles to be used as delivery vehicles for an NF-κB TFD treatment in in vitro models of 
rheumatoid arthritis and cystic fibrosis.  
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1. Introduction 
Nucleic acid based drug constructs are promising therapeutic candidates and have garnered a 
great deal of interest in recent years. These constructs, including DNA plasmids, DNA 
oligonucleotides, and RNA oligonucleotides, have the potential to target a variety of diseases 
through the control of genetic material. Plasmid therapy, for example, is based on the 
replacement of a defective gene with a new intact one via plasmid integration. RNA 
oligonucleotides (siRNA, miRNA) are naturally occurring, but can also be exogenously 
supplemented, and are essential for controlling certain aspects of gene expression. Finally, DNA 
oligomers have emerged as antisense oligonucleotides and transcription factor decoys, which 
bind to specific DNA sequences or transcription factors, respectively. The following work will 
describe the use of a transcription factor decoy against NF-kB.  
Despite the interest in and potential of nucleic acid drugs, the primary barrier to clinical use 
of these materials is a safe and effective method of delivery. Nucleic acids are very unstable in 
vitro, as well as in vivo, and are subject to degradation by nucleases and other enzymes. In 
addition, charge interactions between the negatively charged nucleic acid backbones inhibit entry 
into negatively charged cell membranes. In vivo, nucleic acids undergo rapid clearance via 
glomerular filtration, or recognition and intracellular degradation. In sum, the two major barriers 
to nucleic acids being effective therapeutics are the negative charge which prevents cellular 
uptake and the short nucleic acid molecules lack of stability and susceptibility to nuclease 
activity [1]. To overcome stability problems, chemical modifications such as phosphorothioate or 
methyl phosphonate are often applied to the nucleotide backbones [2]. While these modifications 
enhance stability, they do not necessarily lead to increased delivery efficiency, resulting in the 
need for a high dose and frequently repeated delivery. This is not a sustainable method for 
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delivery, as phosphorothioate nucleic acids have been shown to have a concentration dependent 
toxicity [3, 4]. 
Methods that do not involve directly modifying the nucleic acid therapeutic itself, such as 
viral vectors, cationic lipid formulations and more recently, cationic polymer formulations, exist 
to overcome the barriers to nucleic acid delivery. The advantages and disadvantages of these 
different methods will be discussed in chapters two and three. In general, drug delivery systems 
for nucleic acids must have the following attributes: biocompatibility and biodegradability, 
reticuloendothelial system avoidance, non-immunogenicity, cellular uptake capability, and cell 
or tissue specificity [5]. Recently, polysaccharides have attracted interest as materials for drug 
delivery systems due to an inherent lack of toxicity, a propensity for degradation with existing 
enzymes, and in some instances, innate bioactivity[6]. This dissertation describes the use of a 
polysaccharide based polysialic acid-N-trimethyl chitosan (PSA-TMC) nanoparticle system as a 
non-immunogenic, non-toxic, biodegradable delivery system for small nucleic acids. Although 
chitosan-nucleic acid polyplex systems have been reported previously, this system is 
distinguished by the addition of polysialic acid, a polymer that has been shown to impart stealth 
properties on  nanosystems [7]. In addition, when compared to other chitosan based NA delivery 
systems, PSA-TMC nanoparticles have smaller sizes and lower polydispersities, making them 
more suitable to drug delivery applications [8].  
A transcription factor decoy ODN is a short nucleic acid sequence that mimics the nuclear 
binding site associated with specific transcription factors, but does not contain any genetic 
coding sequences, effectively preventing transcription factor activity beyond initial binding. To 
demonstrate anti-inflammatory activity, the NF-κB decoy ODN-coated PSA-TMC nanoparticles 
were administered to several in vitro models, including CF via interleukin-1β (IL-1β) or 
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Pseudomonas aeruginosa lipopolysaccharide (LPS) stimulation of IB3-1 bronchial epithelial 
cells, CF via co-culture with  P. aeruginosa bacteria, and RA via SW982 synovial sarcoma cells 
stimulated with interleukin-1β, as well as synoviocytes isolated from RA joint tissue. Using these 
models, we show that free ODN and PSA-TMC nanoparticles coated with scrambled ODNs do 
not have substantial impacts on the inflammatory response; however, decoy ODN-coated PSA-
TMC nanoparticles were able to reduce the secretion of interleukin-6 and interleukin-8, as well 
as expression of granulocyte-macrophage colony stimulating factor.  
In sum, PSA-TMC is a non-toxic, non-immunogenic, biodegradable nanoparticle system 
expected to effectively incorporate and safely deliver small nucleic acids. This claim has been 
investigated using an NF-κB inhibiting oligonucleotide in several in vitro models, as described in 
the following sections. 
The thesis is constructed as follows: general background information regarding drug delivery 
system design challenges (chapter two), followed by specific background information regarding 
inflammation in RA and CF, concluding with the goals to be achieved and hypotheses tested by 
this work (chapter three). Chapter four will be devoted to adaptation of PSA-TMC nanoparticles 
to be DNA carriers, while chapters five-seven will focus on detailed description of development 
and testing on in vitro models, and chapter eight will summarize the work described and discuss 
potential future directions of this project.  
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2. Challenges of drug delivery 
This chapter was adapted from a textbook chapter written by P.R. Wardwell and R.A. 
Bader published in Engineering Polymer Systems for Improved Drug Delivery, and provides an 
overview of the challenges provided by the environment of the human body and the chemical 
and physical characteristics of therapeutics themselves for drug delivery applications. Although 
not everything discussed in this chapter is relevant to the specific work subsequently described in 
the thesis, the information presented here is vital to understand the complexity of drug delivery, 
and the degree of thought, planning, and experimentation that must go into designing new drug 
delivery methods.  
Abstract 
Recent advances in drug development have led to the discovery and production of a 
variety of therapeutic molecules, with the potential to target and treat many diseases [9]. Their 
use is somewhat limited, however, by the drug delivery methods available today, and the 
obstacles put in place by the human body. The body is essentially a complex network of 
compartments within which the desired sites of action lie. In 
order to reach these targets, the drug molecules have to cross a 
variety of boundaries, usually in the form of epithelial 
membranes or mucosal barriers, as well as face exposure to a 
harsh environment of degrading enzymes and varying pH levels 
[10]. Therapeutic characteristics including hydrodynamic radius, 
charge, hydrophilicity, and permeability can affect movement [11]. The impact of these obstacles 
on bioavailability differs among users, resulting in variable therapeutic efficacy [12].  
Fig. 1: Several intertwined 
factors affect the design of a 
drug delivery system. 
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In general, the ability of the drug molecule to reach its target organ and have the desired 
effect is hindered by obstacles that can be broken into three interrelated categories as follows: (1) 
in vivo drug solubility, (2) in vivo drug stability and (3) physical barriers to absorption (Fig. 2-1) 
[13, 14]. In order to travel to the site of action and have maximum efficacy, the drug must be 
soluble and stable within the aqueous environment of the body.  Furthermore, soluble and stable 
therapeutic agents are associated with increased ability to permeate the physical barriers that 
hinder absorption. Based on the obstacles introduced above, development and enhancement of 
methods for improving delivery of therapeutic molecules that lack stability and solubility is 
imperative. Many methods for improved delivery rely on polymer based compounds in the form 
of (1) implantable networks for controlled release; (2) carrier systems including nanoparticles, 
liposomes, and micelles for therapeutic encapsulation; and (3) polymer-drug conjugates.   
This chapter will provide an overview of the various physical and chemical challenges 
encountered in the physiological environment that prevent therapeutics from reaching the site of 
action. Additionally, the concept of dosing maintenance and the therapeutic window will be 
explored. Finally, a brief introduction will be given on how polymer based carrier systems and 
polymer conjugates can be used to overcome these barriers 
2.1. History of challenges in drug delivery 
As science has advanced, the discovery of potential drug molecules has increased.  
However, due to complexity of the human body and the drug molecules themselves, application 
of new therapeutics is somewhat limited. Thus, as new drug discoveries were made, advances in 
delivery mechanisms became increasingly necessary [15]. To optimize efficacy and minimize 
negative effects, a high concentration of non-metabolised drug must reach the site of action 
preferentially over non target tissues [16]. 
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In the mid 1900s, progess in the developent of new drug delivery systems was initiated. 
Until this time, the majority of drugs were delivered through conventional methods such as 
injections (parenteral, intramuscular, subcutaneous.), oral delivery (solutions, tablets) or 
transdermally, in the form of cream or ointment [17]. These methods, although effective at the 
time, each come with disadvantages.  The injection route is painful, invasive, and often times 
requires administration by a trained clinician; thus patient compliance is low, resulting in a 
reduced therapeutic efficacy [18]. Additionally, since the drug is often times injected directly 
into the blood stream, the effect is somewhat short lived, and then the potential for sustained 
effect is diminished.  Oral delivery methods are associcated with high patient compliance, 
however many drug molecules can not survive the harsh environment of the gut or be absorbed 
through the intestinlal epithelial barrier [19, 20]. Topical delivery again generally improves 
patient compliance, however this method is limited to local delivery, as many therapeutics 
cannot diffuse thorugh the protective layers of the epidermis [21]. Drug delivery systems aim to 
mitigate the limitations of these conventional delivery methods.   
In the 1950’s a break through in oral drug delivery systems was made with an 
encapsulation methods known as the Wurster process [22]. This in turn led to the development of 
other microencapsulation methods. In the late 1960’s, Alejandro Zaffaroni, a pioneer in drug 
delivery research, designed the first controlled release drug delivery system in the form of a 
transdermal patch [23]. His research is conisdered by many to form the foundation of all 
subsequent drug delivery research. 
Liposomal systems were also developed in the 1960’s for controlled release. A liposome 
is an artificial vesicle made from two lipid bilayers, resulting in a hydrophilic outer shell and 
inner core, with a hydrophobic layer between the two. The dual natured attitude toward water 
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allows for encapsulation of both hydrophobic and hydrophilic drug molecules within the carrier 
system. Current liposomal systems incoroporate poly(ethylene glycol) to reduce undesired 
uptake by the reticuloendothelial systems. Liposomes are beyond the scope of this project, but 
are covered in depth in many references[24-28].  
Polymer-drug conjugates, also referred to as polymeric pro-drugs, have been explored as 
drug delivery systems. Through conjugation, the drug molecule can be held in an inactive form 
until release at the site of action, thereby reducing non-specific toxicity and enhancing 
therapeutic efficacy. Conjugation can increase therapeutic stability and solubility. Drug delivery 
systems, particularly those based upon polymers, have allowed scientists to surpass the barriers 
frequently encountered in vivo.   
2.2.  Physical barriers 
In order to reach the systemic circulation 
and/or the site of action, all molecules must cross a 
series of physiological barriers, particularly epithelial, 
mucosal, and endothelial membranes. These 
membranes exist throughout the body, with varying 
complexity, thickness,  and permeability [29]. 
Membrane properties allow some molecules to cross 
easily, while others are not able to cross at all. The 
barriers to drug delivery, and their associated 
properties will  be discussed in detail in this section.    
2.2.1.  Epithelial membranes 
Fig. 2: Epithelial cells can be classified 
by morphology and alignment.   
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Epithelial membranes line the interior and exterior of numerous organs. As individual 
organs serve distinct purposes and functions, epithelial membranes differing in cellular  
morphology and arrangement are utilized. The epithelium functions mainly in protection and 
transport, but also assists in the regulation of secretion, absorption, excretion, filtration, and 
diffusion of molecules, such as nutrients, waste, and drugs [30, 31]. As shown in Fig. 2, 
epithelial cell shape can be categorized as squamous, cuboidal, or columnar [32]. These cells can 
be arranged into layers by a process known as stratification. Squamous cells are generally flat 
and wide, as illustrated in Fig. 2 (A,B).  Consequently, these cells are typically found in areas 
with a high amount of material exchange. The lungs, for example, utilize a simple squamous 
epithelium [Fig. 2 (A)] to allow for rapid exhange of 
gases, as thinner membranes are easier to cross. Cuboidal 
cells, as shown in Fig. 2 (C,D), are most commonly 
found in the epidermis and mainly function as structural 
maintenance cells.  Like the simple squamous cells of the 
lungs, columnar epithelial cells [Fig. 2 (E)] are also 
found in areas that require a large surface area for 
material exchange; however, this morphology facilitates 
greater regulation of the exchange. As columnar cells are 
more elongated than squamous cells, they allow for an 
increased number of lateral cell junctions that regulate 
the connectivity of the membrane. For example, a simple 
columnar epithelium is found in the small intestine to allow for the absorption of ingested 
nutrients.  Columnar epithelia cells can be specialized with cilia that sweep unwanted particles 
Fig. 3: Tight junctions, adherens 
junctions, desmosomes, and gap 
junctions serve as connections 
between epithelial cells and act to 
reduce the membrane permeability of 
molecules.   
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away from the area, enhancing the protective nature of the the membrane. Ciliated columnar 
cells are found in other areas aside from the small intestine, including the respiratory passages. 
Additionally, specialized cells known as goblet cells are often scattered among other columanr 
epithelial cells. As will be discussed further below, goblet cells secrete mucus that protects the 
body from potential pathogens and provides a medium for transport. As a general rule, as the 
complexity of an epithelial membrane increases, the permeability of molecules, including drugs, 
decreases.   
Contact between neighboring epithelial cells is provided by several types of cell 
junctions, which can reduce permeability of the membrane to select molecules. These junctions 
include tight junctions, adherens junctions, desmosomes, and gap junctions (Fig. 3). Tight 
junctions are paracellular connections often found towards the apical surface, that seal off the 
pathway between cells, preventing harmful substances as well as therapeutic molecules from 
traveling through the membrane [33]. Tight junctions are composed of transmembrane proteins 
with adhesive properties including occludins, claudins, and recently discovered tricellulin [33]. 
Adherens junctions are tyically located below the tight junctions. The primary compenents of 
these cells are cadherins, which are adhering proteins requiring the presence of calcium to 
maintain adhesiveness. These junctions include actin and myosin filaments on the intracellular 
side of the membrane, resulting in an ability to generate contractile force, which in turn acts to 
control and maintain the cells proper shape and tension. The combination of tight and adherens 
junctions is referred to as the junctional complex [33]. Desmosomes are the next type of junction 
found moving away from the apical surface. Desmosomes are also composed of calcium 
dependent adhesive molecules; however, they are specifically called desmosomal cadherins. 
Desmosomes primary job is to connect epithelial cells to each other on the lateral surface, giving 
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the membrane strength and durability. They differ from tight junctions in their level of 
permeability. As desmosomes primary function is not to create a seal between two 
compartments, the level of permeability is much higher. Unlike the other junctions discussed in 
this section, gap junctions allow for transport between cells and  do not have a significant role in 
strengthening cell-cell structural connections. They can be thought of as small, water-filled 
channels spanning the intracellular space between two adjacent cells. The channels themselves 
are composed of proteins called connexins, which assemble to form a ring  structure and are able 
to span the intracellular space.   
The major limiting factor to absorption of orally administered drugs is the low 
permeability of the gastrointestinal epithelial membrane [34]. Within the gastrointestinal tract, 
drug absorption occurs primarily in the lower portions of the small intestine where the tight 
junctions, and consequently the epithelium, are most permeable [35]. This leakiness of tight 
junctions is associated with a decreased transepithelial electrical resistance (TEER). The 
realization of the importance of tight junctions and TEER in trans-epithelial movement has led to 
the development of several methods to enhance permeability. For example, several investigators 
have found methods to target occludins and claudins, the primary proteins involved in tight 
junctions  [36, 37]. While useful for drug delivery applications, the disruption of tight junctions 
also reduces the protective function of the epithelial membrane; so application of tight junction 
modulation must be highly specific and easily reversible.   
  Rather than targeting intercellular delivery through the tight junctions, other 
investigators in the realm of drug delivery have focused on enhancing absorption through the 
primary columnar epithelial cells of the intensitine, the enterocytes. Enterocytes posess villi and 
microvilli on the apical surface that increase the surface area for absorption [38]. Among 
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enterocytes are specialized cells known as M cells, or membranous cells. They typically are 
found covering sections of lymphoid tissue known as Peyers Patches.  M cells present antigens 
that can be targeted to enhance the efficiency of the transcytosis of macromolecules and non-
bioactive molecules relative to enterocytes [39]. Enterocytes produce the glycoprotein enzymes 
necessary for transporting materials across the epithelia. Recently, enterocytes were found to 
express many of the same drug metabolising enzymes originally thought to only be found in the 
liver [40]. Actions such as co-administration of enzyme competitor molecules to decrease the 
catalytic activity of enzymes (belonging to the Cytochrome P450 family, see Section 2.3.1) on 
the primary administered drug can be taken to enhance absorption and efficacy. Absorption can 
be further hindered by other columnal epithelial cells, goblet cells and ciliated epithelial cells 
[41].  Goblet cells secrete mucus that forms the basis of the mucosal membrane, as discussed 
below. Ciliated cells hinder absorption through the enterocytes by creating drug molecule 
movement [41].   
Transdermal drug delivery is another favored non-invasive route of administration 
hindered by the relative impermeability of the epithelial membrane. The major limiting factor of 
transdermal delivery is the outermost layer of skin known as the stratum corneum. This layer is 
between 10 and 20 um thick and can be thought of as a brick and mortar type of system; where 
the bricks are the cells, composed mainly of cross linked keratin, while the mortar is a dense 
mass of extracellular matrix proteins and lipids. This architecture requires drug transport to take 
a tortuous path of diffusion through the intercellular lipid mass. Thus, only a limited number of 
molecules, specifically those that are lipophilic, have a low effective dosing requirement, and 
possess a  molecule weight of <500 daltons, can travel this route [42]. Below the stratum 
corneum is the avascular epidermis, composed primarily of squamus epithelial cells near the 
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stratum corneum and cuboidal epithelial cells approaching the demis [43]. The epidermis 
provides another non-vascularized barrier that must be traversed by the drug before reaching the 
dermis, the desired destination of most transdermally administered drugs.  This is the inner most 
layer of the skin epithelium where blood vessels and nerve endings are contained [42].    
2.2.2.  Endothelial membranes 
Drugs that enter and exit systemic circulation must cross the endothelial barrier provided 
by the blood vessels. The anatomy of blood vessels varies with the type; however, each artery, 
vein, and capillary consists of a thin, inner membrane of squamous endothelial cells, which 
provides the main barrier to drug absorption [44]. In most healthy systemic vessels, this 
endothelial sheet is continuous with cells, connected by impermeable tight junctions and 
adherens junctions.  
Capillaries, consisting of a single endothelial membrane and a small amount of 
connective tissue, are the most common type of blood vessel and the site of blood/tissue-material 
exchange. Therefore, capillaries are of interest in many drug delivery applications. The capillary 
endothelium can be targeted using ligands specific to receptors expressed by endothelial cells. 
Angiogenic vessels associated with tumors and inflamed tissue provide several examples of the 
specific targeting mechanism.  For instance, the endothelium of newly formed vessels often 
overexpress key proteins and molecules, including vascular endothelial growth factor (VEGF), 
adhesion molecules such as vascular adhesion molecule (VCAM) and e-selectin [45]. 
Atherosclerosis, a disease characterized by vascular inflammation, stiffening, and plaque 
buildup, also is characterized by upregulated adhesion molecules (VCAM-1, ICAM-1, and 
selectins).  Potential plaque rupture provides further prospective targets, as proteins such as 
fibrin are released into the vessel near the plaque [46]. Additionally, endothelial cells contain 
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vesicles specifically designed to transport materials across the cytoplasm [47]. In highly 
angiogenic states, as often associated with pathologies such as tumor growth and inflammation, 
the capillary endothelium becomes increasingly discontinuous. This discontinuity that results 
from the rapid and somewhat disorganized assembly of vessels can be used to facilitate enhanced 
permeation and retention (EPR) of drug molecules, as will be discussed in subsequent sections 
[47].    
2.2.3.  Mucosal membranes 
Many epithelial layers, particularly the gastrointestinal tract membrane, are accompanied 
by another barrier membrane known as the mucosal membrane. The mucosal membrane contains 
a viscoelastic, gel-like substance, mucus, comprised of the glycoprotein mucin. The mucosal 
membrane has several physical and chemical properties that affect the absorption and 
bioavailability of therapeutics [48]. For example, the diffusion coefficients of various 
macromolecular compounds in mucus is typically 30-50% of the diffusion coefficient of the 
same compounds in an aqueous environment, indicating much slower movement [49, 50]. 
Furthermore, mucosal membranes can serve as physical barriers to absorption.  The viscoelastic 
properties of mucus result in entrapment of compounds and agglomeration of particles. This 
agglomeration effectively increases the size of compounds and, thus, contributes to the reduction 
in the diffusion coefficients [50].   
 
2.2.4.  Routes of transport  
There are several classifications regarding how a molecule moves across biological 
berriers. Active transport (requiring an energy input) and passive transport (not requiring an 
energy input) transport are the two main categories of movement, with passive transport having 
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numerous sub categories.  Transport mechanisms can also be divided into paracellular (between 
cells) and transcellular (through cells) routes. Fig. 4 provides a pictoral representation of the 
different transport routes. 
The structure of the cell 
membrane plays a significant role in 
drug transport.  Cell membranes are 
composed of phospholipid bilayers, 
with hydrophilic head groups on the 
edgesand hydrophobic tails 
composing the core. This structure 
imposes the following limitations on 
types of drugs which can cross the 
membrane by transcellular passive 
diffusion: (1) the drug must be lipid 
soluble, (2) the drug must possess a 
low molecular weight,  and (3) the 
drug must be in a position to travel 
from an area of high concentration to 
an area of low concentration.  Drugs can also cross a membrane by passive diffusion 
paracellularly. This type of transport requires the drug molecule be water soluble, of low 
molecular weight, and be traveling along a concentration gradient.  In both paracellular and 
transcellular passive diffusion, the driving force is the concentration gradient. The concentration 
gradient is the fundamental idea behind all types of diffusion, and modeled by Ficks Law.  
Fig. 4: The general paths a drug molecule can use to 
cross a membrane.  Typically, small, polar molecules 
(purple dots) can passively diffuse across an epithelial 
membrane by passing between the cells. This is 
particularly prevalent in the lower portions of the small 
intestine,. Lipid soluble molecules have the ability to 
diffuse accross a membrane, but not between cells (green 
dots). 
15 
 
Depending on the cellular architecture of the barrier, the drug molecule may have to diffuse 
through or between more than one layer of cells. Under these circumstances, each different layer 
must be accounted for, resulting in an effective barrier to drug absorption. For a given drug 
molecule undergoing passive diffusion, the rate of absorption will be linear with respect to the 
concentration [51].   
  A variation on passive diffusion is a process known as facilitated diffusion.  This 
process still relies on the concetration gradient as the driving force and requires no energy input, 
however membrane-embedded proteins are required for entry to the cell. Facilitated diffusion 
can be thought of as two different categories as well: carrier mediated transport and channel 
mediated transport. Carrier mediated transport requires transport proteins, which function by 
binding to the molecule to be transported, moving across the membrane, and releasing it on the 
other side. No direct change is made to the transport protein in this process. These proteins are 
structurally selective for the drugs that they transport  and are saturable. Thus, the maximum rate 
of absorption will dependent on the concentration of receptor, not the concentration of drug [52]. 
Channel mediated diffusion requires continuous, aqueous pores spanning a lipid bilayer 
membrane.  Charged or polar drugs are typically able to travel through these channels faster than 
passive diffusion through the membrane; therefore, their rate of absorption is increased [52]. 
The transport mechanisms discussed above have relied on the concentration gradient for 
the driving force and therefore have not required any outside input of energy. In constrast, active 
transport most often refers to the the movement of solute against a concentration gradient and 
does require an energy input. In drug delivery applications, active transport typically refers to 
transmembrane pumps that use ATP to transport drug molecules from areas of low concentration 
to high concentration.  Protein pumps can move molecules either into or out of a cell and are also 
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crucial in maintaining ion balances across membranes.  Some examples of transmembrane 
protein pumps include the sodium potassium pump (Na+/K+), the sodium hydrogen pump in the 
gastrointestinal tract, and the calcium ion pump [52, 53].    
2.2.5.  The blood brain barrier 
The blood brain barrier (BBB) is a general term for the system of membranes acting in a 
protective manner to keep the central nervous system (CNS) impermeable to molecules from the 
systemic circulation. The CNS is the most convenient route of delivery for therapeutics capable 
of treating nervous system disorders, including 
medications for the treatment of stroke, many 
types of cancer, Alzheimer’s disease, and human 
immunodeficiency virus (HIV) [54].  
Unfortunately, the physiology of the BBB 
makes transport into the CNS from systemic 
circulation difficult. The BBB is comprised 
mainly of cerebral microvascular endothelial 
cells, which give rise to structural differences in 
brain capillaries compared to other systemic 
capillaries. As shown in Fig. 5, endothelial cells lining the brain capillaries contain tight 
junctions, creating a less permeable barrier between the blood and the CNS [55]. Non brain 
capillaries contain endothelial cells as well, but the spaces between them generally contain more, 
as well as larger, openings than brain capillaries. As a result, molecules <500 Da can passively 
diffuse through the openings and pass into the tissues. In contrast, the tight junction regulated 
brain capillaries do not allow for diffusion between cells, leaving only membrane diffusion as a 
Fig.5: A representative cross sectional view 
of the blood brain barrier. The BBB is 
comprised of the endothelial cells of brain 
capillaries connected by nearly 
impermeable tight junctions.  Additionally, 
the astrocytes, pericytes, and neurons lining 
the capillaries further hinder transport of 
drugs into the CNS.  
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means of transport into the brain [56].  Small (<500 Da), lipophilic drug molecules have the best 
chance of achieving transport with this process[56]. This requires solutes to diffuse through two 
membranes; the lumenal and ablumenal membranes of the endothelium. Furthermore, 
surrounding the ablumenal membrane of the capillary are astrocytes, pericytes, and neurons, 
which provide additional membrane barriers between the systemic and brain blood flows [57].   
A number of transmembrane transport systems are present in the endothelial cells of the 
BBB.  These transporters are generally facilitative, with the main function being to allow for the 
uptake of nutrient materials [58]. These transport systems can be exploited in applications to 
improve delivery to the BBB. In addition to facilitative transport systems, transmembrane 
transport systems exist within the endothelial cell layer that function to keep molecules out.  
These transmembrane transport systems, known as efflux pumps, are also present in the 
intestinal track and liver.  Many efflux transport pumps employ ATP hydrolysis as energy to 
power the pump, and thus are termed ATP Binding Cassette family proteins, (ABC) transporters.  
This class of proteins is very large and structurally diverse, giving rise to individual ABC pump 
subfamilies.  The subfamilies are denoted with letters A-G, and are distinguished from each other 
by the types of drugs they transport. In general, ABC substrates are typically hydrophobic or 
amphipathic, and the differences that distinguish the substrates for each subfamily are subtle. For 
example, lipids, bile salts, and peptides are all transported by subfamilies A, B, and G.  
Additionally, organic anions, as well as conjugates with anionic residues such as glutathione, 
sulfate, or glucoronyl have receptor specificity for ABCC [59, 60].  
P-glycoprotein (P-gp) is a well characterized efflux pump present in the BBB. This 
protein associated with the expression of the multi-drug resistant gene family (MDR family). A 
variety of lipophilic drugs have been identified as substrates for P-gp.  For example, cyclosporine 
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A (CysA), an immunosuppressive agent, has been shown to be hindered by P-gp when crossing 
the BBB. However, in the presence of agents shown to suppress the MDR genes, including 
chlorpromazine and various steroid hormones, uptake of CysA can be significantly improved 
[61]. P-gp is a transporter present in many other tissues, including the liver, intestines, and 
kidneys, and will be further discussed in Section 2.4.1. 
2.3.  Metabolic and chemical concerns 
The mechanism of transport of drug in the body depends on several chemical and 
physical properties, including molecular weight, hydrodynamic radius, lipid solubility, partition 
coefficient, and polarity  [62]. To affect the target tissue, a drug must enter the cells in an active 
form.  In general, drugs are metabolized, resulting in either a decrease in the usable concentration 
of drug molecules or an increase in the  amount of metabolite concentration that will have an 
undesirable effect on the target tissue. Knownledge of physiochemical properties of drug 
molecules in vivo is essential for predicting therapeutic efficacy. This section will discuss the 
effects of drug metabolism on drug absorption, including the use of transport proteins and 
enzymes to hinder or aid absorption.   
2.3.1.  The first pass effect 
First pass metabolism (first pass effect) occurs mostly in oral delivery applications when 
the concentration of administered therapeutic is reduced by metabolic efforts of the body before 
reaching systemic circulation.  The principle organs involved in first pass metabolism are the 
small intestine and the liver [63].   
2.3.1.1. Enzymatic hepatic metabolism 
Despite the many barriers to absorption in the intestine, many drugs are able to cross the 
epithelium and enter systemic circulation.  However, they are not yet in the clear to travel to the 
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site of action and effect a response. All drugs absorbed through the intestinal epithelium are 
carried to the liver via the hepatic portal vein. The liver is responsible for breakdown and 
metabolism of a variety of substances, including steroids, sterols, bile acids, and ecosinoids. 
Though vital for normal function, the liver provides an undeniable barrier to drug delivery.  Drug 
molecules with structural or chemical properties similar to those of the natural liver substrates 
will be metabolized in the liver via the same metabolic pathways. Some drugs (for example the 
glyceryl trinitrate, used to treat angina, and lidocaine, an analgesic) are rendered useless when 
delivered orally due to extensive metabolism by the liver [64].  
The Cytochrome P450 (CYP) enzyme family is the major source of enzyme activity 
involved in hepatic metabolism. The CYP450 family is a large gene family composed of 57 
different members.  The majority (70-80%) of phase one drug metabolism is carried out by about 
15 of these, belonging to classes designated CYP1 and CYP3.  Phase one metabolism refers to 
modifications of the basic structure of a drug molecule. CYP enzymes can catalyze 
modifications, including hydroxylations; O, S, and N dealkylation, oxidation, demethylation, and 
deamination.  The result of these modifications is structurally changed metabolites, which are 
either eliminated immediately, used as substrates for phase two metabolism, or retain the ability 
to be therapeutically active. Codeine, for example, typically undergoes an O-demethylation 
catalyzed by CYP2D6, resulting in a structural change to morphine, a drug with an increased 
activity level [64]. Although the goal of phase one metabolism is generally to detoxify 
compounds transported in the bloodstream, the opposite effect can sometimes occur, resulting in 
a secondary metabolite that is more toxic than the original drug molecule.  For instance, phase 
one metabolism of chemotherapeutic Tamoxifin results in a metabolite with genotoxic 
hepatocarncinogenic properties. In instances such as this, phase two metabolism is extremely 
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important in preventing the toxic molecule from not only damaging the liver, but also from 
entering systemic circulation once again [65].  
Phase two metabolism is carried out by a class of enzymes known as transferases.  As the 
name might imply, transferases catalyze the transfer of material.  In the case of drug metabolism, 
the transferase catalyzes the transfer of a hydrophilic moiety from a donor molecule to the 
metabolite molecule, typically reducing the toxicity or allowing for neutralization reactions to 
occur.  Like CYP enzymes, transferases are also typically thought of as gene superfamilies.  
Some of the major transferase families include glutathione-S transferase (GST), 
sultphotransferase (SULT), N-acetyltransferase (NAT), and UDP-glucuronosyltransferase 
(UGT). GST catalyzes reactions with non-polar compounds, SULT results in sulphation of 
steroid hormones and bile acids, NAT results in acetylation of amine groups, and UGT leads to 
glucuronidation of molecules, such as the hepatic product bilirubin, pain reliever acetaminophen 
(toxic in instances of overdose), pain reliever morphine, and other non-steroidal anti-
inflammatory drugs (NSAIDs) [64]. Toxicity of a phase one metabolism by product is highly 
dependent on its rate of production in relation to its rate of reaction with phase two metabolizing 
transferases.    
2.3.1.2. Enzymatic intestinal metabolism  
In addition to physical barriers preventing absorption, metabolic enzymes, including 
lipases, proteases, and glycosidases are present in the gastrointestinal tract to breakdown ingested 
food and release energy and nutrients [66]. While highly efficient at providing energy and 
nutrients, these enzymes are also responsible for the degradation of drug products, preventing 
absorption and/or resulting in a loss of function. Two major proteins responsible for 
metabolizing drugs in the gastrointestinal tract are CYP3A and the P-glycoprotein efflux pump 
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[67]. These complexes are found in several locations, including the intestine and liver. In the 
intestinal tract, they are often found within the membrane of individual enterocyte cells, the 
primary cells for drug absorption.  Methods to circumvent CYP metabolism of drugs in the 
intestine include co-administration of a CYP inhibitor or inducer. A simple method of inhibition 
is co-administration of a secondary drug which competes with the primary drug for access to the 
active site of a CYP enzyme. Drugs with a high affinity for CYP450 that can be used as 
secondary drugs for competition include cimetidine, (used to treat ulcers), ketoconazole (used to 
treat fungal infections) and Indinavir, a protease inhibitor used to treat viral infections [64]. 
Additionally, a metabolite of the primary administered drug may sometimes form an inactive 
complex with the catalytic site of the CYP enzyme. This method of inhibition is often known as 
mechanism based P450 inhibition [68]. CYP inhibitors decrease the effect of the enzyme, 
allowing for increased absorption of drugs including sirolimus, cyclosporine, and tacrolimus 
[67].   
The most prevalent and arguably most important enzyme of the CYP family in intestinal 
metabolism of drug molecules is CYP3A4. Found in large quantities in the liver, CYP3A4 is also 
present in the jejunum portion of the small intestine, primarily located on the villi[38]. Studies 
have shown the enzyme activity and concentration of jejunum CYP3A4 to be equal to that of the 
microsomes of the liver [69]. CYP3A4 has a broad range of structurally diverse substrates, with 
an equally broad range of therapeutic function; however, hydrophobicity is a commonality across 
substrates. Biotransformation reactions of drug molecules by CYP enzymes are typically 
considered to be phase one, referring to a basic structural change of the molecule [38].  
2.3.2. Efflux systems  
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Efflux systems are energy dependent transport systems whose function is to protect the 
body by preventing harmful substances from traversing membranes and entering other body 
compartments [66].  They are present in many different areas of absorption, but play the most 
significant role in the gastrointestinal tract and the blood brain barrier.  The most well-known 
and well classified efflux pumps are members of the P-gp family, as mentioned in brief above.  
P-gp was first characterized as the transport system behind tumor resistance to 
chemotherapeutics; as it was able to transport the therapeutic agents out of the cell.  This efflux 
pump is transcribed as a result 
of the multi-drug resistant gene, 
MDR-1 [38]. P-gp has a large 
variety of substrates, similar to 
CYP3A, many of which are 
large and amphipathic [67].  
Additionally, in the intestine, 
expression of P-gp increases 
longitudinally throughout the 
tract, in contrast to the levels of 
CYP3A expression. This results 
in a constant source of 
molecular absorption prevention throughout the gastrointestinal tract, as P-gp’s main effect is to 
pump drug molecules back into the lumen [19].  
In sum, the mechanism of membrane crossing for solutes traveling into the brain is 
usually by receptor mediated transport or diffusion. Properties of the drug molecules can be 
Fig. 6: For drugs with a molecular weight of 500+/- 100 Da, the 
permeability of the BBB has been shown to increase linearly 
with the partition coefficient relative to the square root of the 
molecule weight.   P-gp efflux pump has been shown to account 
for discrepancies, as the outlier drugs in the graph are known to 
be P-gp substrates. 
23 
 
tailored to make crossing the BBB more feasible and efficient. If the molecular weight of the 
molecule in question falls at 500 ±100 Da, the permeability of said molecule increases linearly 
with the partition coefficient of the molecule. This relationship can be shown graphically by 
constructing a plot of the log of permeability vs. log of the partition coefficient divided by the 
square root of the molecular weight, as described by Tsugi and Tamai, and shown in Fig. 6. [61]. 
An alternative to the molecular weight explanation of decreased permeability is the presence of 
the P-gp efflux system.  This system, also present in the gut, serves to restrict transcellular flux 
of drug molecules, thus decreasing permeability.  
2.4.  Physical properties of therapeutics 
Several factors are involved in both the amount of and the extent to which a drug 
molecule will affect the target tissue. In addition to the physiological and chemical properties 
discussed previously, the route of administration and delivery method, dose and release profile, 
as well as physiology changes due to pathology play a role in determining the biological effect of 
a drug molecule.   
2.4.1.  Bioavailability 
Bioavailability is defined as the amount of drug reaching the systemic circulation out of 
the amount of drug that was administered [70]. Careful dosing and administration is a necessity 
for efficacious treatment. The amount of drug available at the desired site of action must fall 
within the therapeutic window [12].   
Achieving reproducible oral bioavailability is particularly difficult because there are 
several factors which must be considered based on the path the drug must travel before reaching 
systemic circulation. In this case, the overall bioavailability (F) is the product of the portion of 
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drug absorbed (Fa), i.e. the fraction that passes into the hepatic portal blood unaffected by the 
enzymes of the gut and intestine, and the fraction of drug that escapes metabolism by the liver 
(Fh) [38, 70]. This value will vary between drugs due to the differential effects of enzymes, 
including CYP and P-gp, on individual drugs.   
In addition to the effect of the body’s metabolism, properties of the drug molecule itself 
have a large impact. Solubility, for example, is one of the leading factors hindering oral 
absorption and reducing bioavailability, and a great deal of effort is being put forth to determine 
methods to increase solubility of therapeutics in aqueous environments [71]. For example, 
chemical modifications to the drug molecules to generate prodrugs with an increased aqueous 
solubility are being explored, as are methods of solid dispersion. Solid dispersions typically 
consist of a hydrophilic matrix material with hydrophobic drug dispersed throughout. The result 
is an increased dissolution rate and higher bioavailability of hydrophobic drugs. The degree of 
therapeutic solubility (or dissolution rate) is dependent on the diffusion coefficient of the drug, 
the concentration of the drug within the dissolution medium, and the solubility of the drug within 
the dissolution medium. Additionally, physical factors, including the surface area of the 
formulation available for dissolution and the thickness of the diffusion boundary the drug must 
travel through, must be accounted for [72].   
2.4.2.  Release profiles 
The amount of drug released into the bloodstream over time is known as the release 
profile. Release profiles typically depend on the dosage form of the drug, the method of release, 
and the properties of the carrier system. These release profiles are often categorized as controlled 
release, pulsatile release, and burst release, as shown in Fig. 7. Controlled release is 
characterized by a gradual increase in the plasma concentration with time until a maintenance 
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concentration is reached. This is often the desired treatment method, although somewhat more 
difficult to attain. Pulsatile release similarly begins with an increase in plasma concentration to a 
desired level, followed by decreases in concentration, which are counteracted with additional 
dosing, maintaining a concentration within the therapeutic window.  Burst release consists of an 
initial dose generating a steep rise in plasma concentration. However, the initial drug release is 
not supplemented with additional doses, resulting in a short time period when the plasma 
concentration is within the designated therapeutic window [73].   
Of particular importance is the carrier system properties, which modulate how the drug 
molecules are released. Diffusion always plays a role in drug release, however depending on the 
properties of the source (i.e. the carrier system), the concentration profile will differ. The two 
primary methods of degradation are bulk and surface erosion (Fig. 8). Surface erosion results in a 
reduction of the overall 
volume of the carrier system 
as degradation occurs at the 
surface of the material. This 
also results in a turnover of 
the surface; a new layer of 
the material is constantly 
being exposed to the 
environment. In contrast, 
bulk erosion does not result 
in a volume reduction; rather, the material is lost uniformly throughout the entire volume of the 
carrier system [74].   
Fig. 7: Three release profiles are commonly observed for drug 
carrier systems. Sustained/controlled release is characterized by 
an increase in plasma concentration until a desired maintenance 
concentration is reached. Pulsatile release is characterized by a 
cyclic fluctuation in plasma concentration. Burst release is 
characterized by a large initial increase in plasma concentration, 
followed by a sharp decline.   
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Different applications require different release profiles, but, as mentioned above, a 
sustained plasma concentration is generally most desirable. For example, release of drugs 
dispersed within polymer constructs, as will be covered in subsequent sections, is dependent on 
the rate of degradation of the polymer substrate, as well as the diffusion rate of the drug.  If the 
degradation rate is slower than the diffusion rate, the release will follow the pattern of bulk 
erosion method. If polymer degradation is faster than 
the diffusion rate, the release will follow the pattern of 
surface erosion [75].  
2.5.  Polymer carriers as a solution to 
challenges 
The term ‘polymer’ refers to a long chain 
molecule composed of many repeating molecules. 
Polymer encapsulation of and/or modification to drug 
molecules increases circulation time of the drugs in the 
body by increasing their size, thereby decreasing the 
amount of filtration by the kidneys [76]. Additionally, 
targeting of drugs to specific sites of pathology can be 
improved by the increase in size due to a phenomenon 
referred to as enhanced permeation and retention 
(EPR) [77]. For example, cancer tumors and sites of 
inflammation show increased angiogenesis and a characteristic “leaky” vessel endothelium (Fig. 
9). The leaky vasculature is caused by rapid and disorganized vessel formation, which results in 
Fig. 8: Surface and bulk erosion are 
two methods for degradation of 
carrier systems.  Surface erosion 
results in a decrease in overall 
volume, shown here by a reduction 
in size. Bulk erosion results in a 
decrease in the amount of material 
within the matrix. 
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larger pore spaces between endothelial cells. Polymeric drug delivery systems may be taken into 
the tissue by transcellular transport, but 
this is a time dependent process and 
generally not efficient. In diseased tissue, 
however, the larger gaps between vascular 
endothelial cells allows for relatively easy 
uptake of the drug carriers [77].   
 In general, polymer carrier 
systems should have several common 
characteristics.  These characteristics 
include (1) an ability to be produced 
easily and on a large scale, (2) applicability to a wide range of drugs, (3) physiological stability, 
(4) biocompatibility, and (5) acceptability by regulatory committees, such as the FDA [78].       
2.5.1.  Colloidal polymer carrier systems 
Several kinds of polymer carrier systems can 
be utilized for drug delivery applications to help 
avoid some of the previously discussed challenges.  
In general, colloidal polymer carrier systems are 
small spherical particles with varying layers and 
thicknesses [76]. The spherical particle shape of 
these formulations increases the surface area of the system, allowing for increased absorption.  
Different particle carrier systems include micelles, liposomes, and nanoparticles [79]. Simplified 
A                                  B                                   C
Hydrophobic Drug
Hydrophilic Drug
Fig. 10: Colloidal polymer carrier 
systems include (A) liposomes, (B) 
nanoparticles, and (C) micelles.     
Fig. 1: EPR facilitates for passive targeting of drug 
delivery systems. (A) Vessels within healthy tissue 
have narrow gaps between endothelial cells, while 
(B) vessels within diseased tissue have larger 
(“leaky”) gaps.  
 
A                                 B 
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versions of these carrier systems are depicted in Fig. 10 and discussed in depth in subsequent 
section.   
Micelles are small, soluble particles that can self-assemble by means of 
hydrophilic/hydrophobic segregation. In addition to hydrophobic interactions, electrostatic 
interactions, metal complexation, and hydrogen bonding of the contribute to micelle formation 
[77]. A block copolymer with separate hydrophobic and hydrophilic segments will have the 
ability to assemble in an aqueous environment such that the hydrophobic segments compose a 
core in the center, while the hydrophilic segments compose a shell surrounding the core, thus 
greatly increasing the aqueous solubility of hydrophobic therapeutics. A popular choice for 
hydrophilic block copolymer sections is poly (ethylene glycol) (PEG), a widely used polymer in 
drug delivery applications, and the gold standard for ‘stealth cloaking’ of carrier systems.  
Stealth cloaking is a means of avoiding non-specific uptake once administered and functions by 
creating an aqueous layer around the particle to avoid detection by the immune system [80]. 
Non-specific uptake by the reticuloendothelial system (RES) is a major obstacle to micelles and 
other small colloidal carrier systems.  The RES is part of the body’s defence mechanism and 
includes cells such as macrophages and monocytes.  These cells are phagocytic in nature, and 
function by engulfing potential threatening substances, eventually accumulating in the liver and 
spleen for degradation and elimination [81]. This poses a problem for drug carrier systems 
because uptake by these cells will reduce the amount of therapeutic in the systemic circulation 
[81].  
Poly-L-amino acids, such as poly (D, L-lactic acid) (PDLLA), are frequently used as the 
hydrophobic portion of micellar block copolymers. For example, Genexol PM, a PEG-PDLLA 
copolymer micelle loaded with the chemotherapeutic paclitaxel, is currently approved for the 
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treatment of breast cancer and is undergoing clinical trials in the US for use in pancreatic cancer 
treatment [82].  Micelle formation is influenced by factors such as the molecular weight of the 
copolymer, the ratio of copolymer blocks to each other, and the amount of polymer involved. 
The minimal amount of polymer necessary to form a micelle is referred to as the critical micelle 
concentration (CMC) [83]. Above this concentration, all additional polymer molecules will be 
formed into micelles.   
 Nanoparticle based drug delivery systems consist of sub-micron sized spherical particles, 
ranging from 10-1000 nm, although the desired size is often around 100 nm [75]. Nanoparticles 
are typically made of a biocompatible, degradable material and contain drugs either dispersed or 
dissolved within a core matrix. Two classes of nanoparticles have been identified based on the 
way the drug is incorporated.  Nanocapsules contain drug molecules confined to the interior of 
the polymeric shell of the particle, while with nanospheres the drug molecules are uniformly 
dispersed within the polymeric matrix system [84].  Once inside the body, drugs can be released 
from the particles by means of diffusion, degradation, swelling, or erosion. Efficacy of 
nanoparticle carrier systems is based on size, particle stability, the amount of drug that can be 
incorporated, the type of drug that can be incorporate (i.e. hydrophilic or hydrophobic drug 
molecules, siRNA’s or DNA for gene therapy, or proteins), and the potential for different routes 
of administration (i.e. oral delivery, inhalation, intravenous).  Nanoparticles have been shown to 
be more effective in intravenous delivery than microparticles; which have an increased potential 
of becoming trapped in the capillaries, some of which are only 5-6 um in diameter. In addition,  
in vitro studies with Caco2 intestinal cells demonstrated that 100 nm particles result in a 2.5 fold 
increase in uptake compared to 1 um diameter particles and a 6 fold increase in uptake compared 
to 10 um particles [85]. Furthermore, particles smaller than 200 nm have the ability to escape 
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processing of the liver and kidney for several circulation cycles, increasing their time in the 
systemic circulation and hence level of effectiveness[86]. However, a diameter larger than 200 
nm will increase the risk for RES uptake, reducing the circulation time and thus the efficacy.     
 As mentioned in brief above, materials used to generate the nanoparticle systems must be 
non-toxic, non-immunogenic, non-inflammatory, and non-thrombogenic (which all fall under the 
general category of biocompatibility).  Additionally, the nanoparticles must be stable, be able to 
avoid detection and uptake by the RES, and be able to be used as carrier systems for a broad 
array of drug types, including proteins, nucleic acids, and hydrophilic and hydrophobic drug 
molecules [81]. Some commonly used materials for generation of nanoparticle systems include 
poly(lactide) (PLA), poly(glycolide) (PGA), poly(lactide-co-glycolide) (PLGA), 
poly(cyanoacrylates), and poly(caprolactone) [75, 81]. Currently, there are no approved drug 
encapsulated nanoparticles or on-going human clinical trials in the US, although a great deal of 
research and development regarding nanoparticle formulations is on-going.  
 Liposomes are another form of small spherical drug carrier systems.  They consist of a 
lipid bilayer (similar to a cell membrane) surrounding an interior space. This morphology allows 
for the entrapment and delivery of both hydrophilic and hydrophobic drug molecules. 
Hydrophobic molecules can be entrapped within the bilayer, while hydrophilic molecules can be 
carried within the core.  The physiochemical properties of the liposomal constituents, including 
the membrane fluidity, permeability, charge density, and steric hindrance have influence on the 
types of interactions the liposomes will have with blood and tissue constituents [87].     
 There are several different types of liposomes. Long circulating liposome’s (LCL) can be 
formed by incorporating hydrophilic polymers into the lipid bilayer to create an aqueous coat on 
the surface, which prevents marking by immune system opsonins and thereby reduces uptake by 
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the RES. An example of this modification is called PEG-ylation, where chains of PEG are 
attached to the particle surface [88]. As discussed above, “stealth” PEG coating generates an 
aqueous layer. Additionally, LCL liposomes can be tailored with ligands to target specific cell 
types. For example, long-circulating liposomes prepared with a PEG coating and loaded with 
Doxorubicin, an anti-cancer chemotherapeutic, were FDA approved in 1995. The efficacy of this 
system has been further improved via linkage to mAb 2C5, a monoclonal antibody which 
specifically targets a variety of tumors [89].   
 Active cationic liposome’s have a high affinity for cell membranes and deliver materials 
to cells by fusing with cell membranes and depositing material into the cell [87]. Nucleic acids 
are the most common therapeutic form delivered with cationic liposomes. As nucleic acids are 
negatively charged, stability is increased when complexed with cationic liposomes for delivery.  
Phase 1 clinical trials were completed for liposomes containing pGT-1, a regulatory gene 
involved in cystic fibrosis, to the respiratory epithelium. These studies showed promising early 
results, however the regulatory gene expression was fairly low and relatively short lived [90].    
2.5.2.  Polymer-drug conjugates 
Another method of increasing targeting specificity of drug molecules and avoiding 
detection and subsequent elimination by the RES is to chemically conjugate polymers to drug 
molecules.  Polymer conjugation serves several purposes. Many chemotherapeutic drugs are very 
cytotoxic, as their efficacy is generally dependent on their ability to cause death of cancerous 
cells.  These same drugs are also often insoluble in aqueous environments, as found in the human 
body.  Covalent attachment of a water-soluble polymer to an insoluble drug molecule increases 
the amount of therapeutic in circulation after administration [91]. In many cases, these polymer-
drug conjugates undergo phase 1 metabolism to remove the inactive polymer and yield an active 
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drug. A current example of a drug-polymer conjugate is poly (L-glutamic acid) conjugated to 
.paclitaxel, yielding PG-TXL. Paclitaxel, a potent anticancer agent, is a molecule with poor 
aqueous solubility that fights cancer by attacking cellular components controlling processes such 
as mitosis, transport, and motility, decreasing growth [92]. While the actions of paclitaxel are 
ideal for attacking tumors, healthy cells are also susceptible to its actions.  Conjugation to PG 
can increase tumor selective uptake and reduce adverse side effects resultant from damage to 
healthy cells.  
Polymer conjugation functions to increase targeting specificity of a particular therapeutic 
to the desired tissue or region of disease.  In addition to polymer alone, receptor specific ligands 
can be grafted to either the conjugated polymer or the drug itself, which results in site specific 
accumulation of the therapeutic [93]. Known as active targeting, this is an effective method to 
reduce non-specific uptake and improve efficacy. 
2.5.3.  Implantable and transdermal drug delivery systems 
 Implantable and transdermal drug delivery devices present methods of prolonged 
administration with relatively stable dosing patterns. These techniques also benefit from the use 
of polymers, both degradable and non-degradable. Unlike the colloidal carrier systems discussed 
in section 2.6.1, these drug delivery devices have been in use for longer periods of time and are 
used more frequently. In general, these devices are used to regulate dosing and increase 
convenience, rather than improve solubility and stability of the drug molecule itself.    
 Implantable devices must be embedded in the body, typically subcutaneously. Therefore, 
there are several important factors that must be met when developing materials for this 
application.  Materials used to construct devices must be chemically inert, hypoallergenic (as to 
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not invoke an allergic reaction from the immune system), non-carcinogenic, and mechanically 
stable at the insertion site [94].   
2.6 Drug delivery systems for nucleic acids 
 Recent developments of nucleic acids as drug constructs present new options for 
treatment of diseases, including cancer, genetic, and inflammatory diseases [95]. However, 
nucleic acid based drugs represent a unique delivery challenge due to their high susceptibility to 
enzymatic degradation in a physiological environment, in addition to an intracellular or nuclear 
site of action.   
2.6.1 Viral vectors as nucleic acid carriers 
 Viral vectors are typically thought of as the most efficient method of gene delivery, in 
terms of getting the genetic material into a cell. Viruses have naturally evolved throughout 
history to transfer foreign genetic material into host cells, making them a strong potential vector 
for nucleic acid delivery [96]. Viral vectors can infect a wide variety of cell types, which is 
advantageous in terms of number of applications, but a drawback in terms of a lack of control. 
Despite attempts to target specific tissues with viruses, success has been limited, and continues to 
present a safety concern. Other problems with viral vectors include potential toxicity, 
immunogenicity, unpredictability of gene insertion site within the host genome, and potential for 
gene inactivation by recombination [97].  
 Several types of viral vectors, including retrovirus, lentivirus, adenovirus, adeno-
associated virus, and herpes simplex virus have been reported in studies involving viruses for 
nucleic acid delivery. Key advantages and disadvantages are summarized in table one [98]. 
Retroviruses function as gene delivery vehicles through retro-transcribing the viral RNA genome 
into DNA, and integrating into the host chromatin. These viruses have been shown to have the 
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ability to attain chronic infection translating to long term gene expression, but are also associated 
with generation of immunodeficiency, or other malignancies [97]. Lentiviruses are similar to 
retroviruses in that they both use RNA. The adenovirus consists of a large family of over 50 
serotypes, isolated from multiple organs and tissues, resulting in the ability to infect many 
different cell types [99]. Despite the wide range of potential targets, adenovirus applications 
remain limited as infection results in an immune response against adenoviral proteins. Adeno 
associated viruses (AAV) are not directly associated with any human disease, and also normally 
require co- 
Vector Advantages Disadvantages 
Adenovirus High transfection efficiency 
Transfects many cell types 
Transfects proliferating/non-
proliferating cells 
Easy to produce 
Remains episomal, transient 
transfection 
Immunogenic with repeated 
administration 
Potential for replication 
competence 
Lack of targeting 
Adeno-associated 
virus 
Ability to establish latent infection, 
prolonged expression 
Cell division not required 
No viral genes in genome 
No targeting 
Potential for mutagenesis 
Difficult to produce 
 
Table 1: A summary of various viral vectors currently in use and being researched for DNA 
delivery applications 
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Herpes simplex 
virus 
Latent expression 
High in vivo efficiency 
 
Cytotoxic 
Lack of targeting 
Requires packaging cell line 
Does not integrate into genome; 
transient expression 
Lentivirus Transfects proliferating/non-
proliferating cells 
Prolonged expression 
Difficult to manufacture and store 
Safety concerns 
Limited clinical data 
Retrovirus Integration into host cell genome 
Prolonged expression 
 
Inefficient transfection 
Mutagenesis 
Requires cell division for 
transfection 
Lack of targeting 
administration of a helper virus to achieve infection. In addition to requiring an additional  virus 
for infection, AAV stimulate the production of neutralizing antibodies after administration, 
limiting their potential for repeated administration [97]. As such, clinical trials using AAV have 
been discontinued due to increased immunogenicity and toxicity [100, 101]. In addition, AAV 
are difficult to store long term and are problematic for Good Manufacturing Practice (GMP) 
standards [102].   
2.6.2 Cationic lipids for gene delivery  
An alternative gene delivery method to viral vectors are cationic lipid based vehicles. 
Cationic lipids used in gene delivery are amphipathic molecules with polar cationic heads and 
long hydrophobic tails. In aqueous environments, these lipids will self-assemble into colloidal 
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structures, or liposomes, with the ability to complex with negatively charged nucleic acids in the 
form of lipoplexes [102]. Lipoplexes are presumed to enter the cell through endocytosis, making 
the size of the particle, as well as the charge, important factors in lipoplex design [103]. Ideally, 
the surface charge of the lipoplex should remain positive to facilitate interaction with the cell 
membranes. This has an impact on the amount of negatively charged nucleic acids that can be 
incorporated into the lipoplex [103]. Many commercially available transfection reagents are 
currently on the market. Of these, Lipofectamine reagents, marketed by Life Technologies, have 
become the most referenced transfection reagent, with the claim of increased efficiency over 
other available reagents. However, these compounds do often exhibit cytotoxicity and are prone 
to accumulation within the liver in vivo, leading to significant nucleic acid payload degradation 
[104, 105].  
2.6.3 Synthetic cationic polymers for gene delivery 
Recognizing the limitations of immunogenic viral vectors and toxic lipoplexes, recent 
research has focused on the alternative use of cationic polymers for complexing with and 
delivering nucleic acids to cells. For example, poly(ethyleneimine) (PEI) is one of the most 
widely used cationic polymer for nucleic acid delivery [106]. However, PEI exhibits 
considerable toxicity toward a variety of mammalian cells [107]. The toxicity is twofold, with an 
initial response to the free PEI remaining in the delivery medium and a delayed response thought 
to be associated with the cellular processing of the PEI/DNA complexes, likely due to an 
increase in free PEI. Free PEI is known to interfere with normal cell processes and negatively 
impact cellular components [106].   
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Natural polymers present another category of potential materials for gene delivery, as 
alternatives to viral vectors, lipids, and synthetic polymers. Relevant carrier systems using 
natural polymers will be discussed in greater detail in chapter three. 
2.7 Conclusion 
As drug discovery research and development continues to advance, development of 
compounds with therapeutic potential is evolving. Many of these compounds cannot be fully 
effective when administered in a traditional manner, invoking the need for the development of 
novel drug delivery systems to complement the advances in drug development. The trifecta of 
issues to overcome when administering drugs to the body as summarized in section one include 
absorption of the drug into various body compartments, stability of the drug and/or carrier 
system in vivo, and finally, solubility of the drug either in vivo, or within the carrier system for 
controlled release applications. Additionally, a well-designed controlled release system with 
ability to provide a zero order release profile is highly desirable. The body contains many 
membranous boundaries which function as protective barriers including the epithelium, 
endothelium, mucosal membranes, and blood brain barrier. These membranes are the targets of 
several methods to increase permeation and enhance bioavailability of drug compounds. The 
stability of the drug and/or its carrier system is an important characteristic to be concerned with.  
If the system does not have adequate stability to be able to reach the site of action intact, its 
payload will likely be distributed elsewhere, resulting in undesirable effects. Once the drug is 
delivered to its site of action, adequate solubility is required for the molecule to enter the cell and 
effect a response.   
This chapter was included to demonstrate the intricacies of drug delivery, as the human 
body contains many barriers and mechanisms to keep substances out. Designing a drug delivery 
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system requires knowledge of these barriers and mechanisms as a means of exploitation, 
combined with an understanding of material properties to in order to design carriers with desired 
traits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
39 
 
3. Background and Significance 
NF-κB decoy oligonucleotides have been proposed as treatment options for several diseases 
where inflammation plays a major role, including both CF and RA. However, clinical 
advancement of NF-κB decoy ODNs have been hindered by a lack of efficacy, due to a high 
degree of instability and a lack of efficient delivery mechanism. This chapter will discuss the 
specific role of NF-κB in RA and CF, provide an introduction to in vitro models of CF and RA, 
and finally provide detailed background of existing DNA delivery methods and their 
shortcomings.  
3.1 Nuclear factor kappa-light chain enhancer of activated B cells (NF-κB) signaling pathway  
NF-κB is a transcription factor involved in the regulation of a variety of cellular 
processes, including cellular growth, apoptosis, and inflammatory and immune responses [108]. 
This transcription factor plays a major role in both 
innate and adaptive immunity and is implicated in a 
variety of human diseases, including autoimmune 
diseases, several types of cancer, and some genetic 
disorders [109].  
NF-κB consists of a family of proteins made up of five 
subunit members: p50, p52, p65, c-Rel, and RelB. The 
most common, and often referred to as “classic”, 
dimerization of these subunits is p50/p65 [110]. While 
other dimerizations have been studied, the p50/p65 
complex will be the focus of the work described here.  
  
Fig 11. Illustration of NF-kB   
activation through ligand-receptor 
interaction 
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Under normal (unstimulated and healthy) conditions, NF-κB is located in the cytoplasm, 
bound to an inhibitor known as IκB (inhibitor of κB). When a receptor involved in the NF-κB 
pathway is triggered by external signals, such as cytokines, growth factors, reactive oxygen 
species, mitogens, bacterial or viral products, activation of a signaling cascade occurs and 
initiates the inhibitor of κB Kinase (IκK) [109]. This kinase phosphorylates the inhibitor protein, 
causing dissociation and leaving the NF-κB dimer free to migrate into the nucleus and initiate 
transcription [111]. In diseases such as RA and CF, NF-κB over-activation is involved with a 
state of perpetual inflammation due to autoimmune factors or chronic bacterial infection. These 
diseases and the role of NF-κB are described in more detail in the following two sections. Fig. 11 
contains an illustration of the NF-kB pathway.  
3.1.1. Cystic fibrosis and NF-kB 
CF is an autosomal recessive genetic disorder caused by a mutation in the CF transmembrane 
conductance regulator protein (CFTR) [112]. CFTR is a transmembrane ion channel involved 
mainly in regulating chloride ions. While CFTR mutations manifest in pathology in multiple 
organ systems, chronic lung infection and inflammation is the greatest cause of morbidity and 
mortality associated with CF, and will be the focus of the work described here [113]. A lack of a 
functional protein leads to a decrease in chloride ion secretion in the CF airway. Combined with 
an increase in sodium absorption due to co-regulation of CFTR the sodium ion channel ENaC, 
defective CFTR results in dehydration in the lung epithelia, contributing to increased production 
of extremely viscous, hard to clear mucus [114]. Mucus buildup is associated with chronic 
bacterial infection, as microorganisms cannot be removed from the airway via normal 
mucocilliary clearance mechanisms.  
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Although chronic inflammation is known to be associated with bacterial infection, certain 
reports suggest that innate inflammation is a component of CF pathology as well. Despite a lack 
of complete understanding of the onset mechanisms, an inflammatory immune response is 
certainly present in CF airways. Elevated levels of transcription factor NF-κB have been shown 
in the CF lung epithelia, and many reports agree that this transcription factor is highly involved 
in excessive inflammation 
seen in the CF airway 
[115].  NF-κB is involved 
in transcriptional 
regulation of several pro-
inflammatory proteins 
directly involved in the 
immune response in CF, 
including granulocyte-
macrophage colony 
stimulating factor (GM-
CSF) interleukin-6 (IL-6) 
and interleukin-8 (IL-8) 
[116]. IL-8 is highly 
involved in neutrophil 
recruitment, and is present 
in elevated levels in the CF airway, while IL-6, also present in elevated levels, is involved in 
immune system activation via B cell stimulation [116, 117].  
Fig. 12: Illustration of a CF airway epithelial cell, and 
activation of the NF-κB signaling pathway. 
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Of the potential bacterial infections associated with CF, one of the most worrisome and 
difficult to treat is Pseudomonas aeruginosa. P. aeruginosa has the ability to genetically adapt to 
acclimate to the environment of the CF airway, allowing survival despite the onslaught of the 
host immune system [118]. P. aeruginosa has been shown to activate the NF-κB signaling 
pathway via the toll-like receptors (TLR); specifically, through TLR-4 by lipopolysaccharides 
(LPS) [113]. Pathway activation initiates a protein kinase targeted to the inhibitor of κB (IκB) 
complex, known as IκK. This kinase phosphorylates IκB, resulting in inhibitor/transcription 
factor complex dissociation, leaving the p50/p65 NF-κB complex free to undergo nuclear 
translocation [119]. This process is illustrated in Fig 12, depicting a typical airway epithelial cell 
response to TLR-4 NF-κB activation. 
TLR-4 plays a major role in inter-kingdom signaling within the CF airway, and the Bader 
Lab has recently been shown to interact and be associated with Pseudomonas Quinolone Signal, 
a quorum sensing molecule secreted from P. aeruginosa[120]. PQS, suggested initially to be 
anti-inflammatory, actually demonstrated increased inflammation in CF airway epithelial cells. 
An in depth investigation revealed that PQS likely binds to the TLR-4 receptor, indicating yet 
another role for this diverse membrane receptor.  
3.1.2. Rheumatoid arthritis and NF-kB 
 Rheumatoid arthritis (RA) is an autoimmune disease characterized most notably by 
chronic inflammation of the synovial membrane of joints. Over time, infiltration of 
inflammatory cells including lymphocytes, plasma cells, and macrophages to the synovial lining 
leads to hyperplasia, and formation of a tumor-like tissue known as pannus [121]. An excessive 
cellular immune response leads to a chronic inflammatory environment, which eventually leads 
to cartilage destruction and bone degradation [122]. In addition to the influx of immune cells, 
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native synovial fibroblasts undergo a phenotypic change, characteristic of immune sentinel 
cells, becoming cells known as activated synovial fibroblasts, or RASF’s [123]. The NF-κB 
pathway is known to be active in RASF’s, leading to production of cytokines, chemokines, and 
matrix metalloproteinase, which contribute to tissue destruction characteristic of RA [123]. 
 While the mechanisms behind RA pathogenesis are not completely understood, it is well 
accepted that an imbalance of pro-inflammatory and anti-inflammatory cytokines occurs, and 
plays a major role in joint destruction. Essentially, the levels of anti-inflammatory cytokines 
(IL-4, IL-10, IL-13) are too low to combat the increased levels of pro-inflammatory cytokines 
(IL-6, IL-8, TNF-α, etc.) released by the immune cells and RASFs of the pannus [124]. Pro-
inflammatory cytokines IL-6, IL-8, and TNF-α are known to be regulated by the NF-κB 
pathway, making this signaling pathway a potential target for lowering levels of inflammatory 
proteins [125].  
 As the cause of RA remains unknown, so does a cure. Current treatments focus on 
modulating symptoms and preventing further joint destruction. Although treatments have 
evolved over the years, researchers and physicians have yet to find a long-term sustainable 
treatment regimen. Disease modifying anti-rheumatic drugs (DMARDs) are typically used as 
the first line of treatment. This category of drugs includes immunosuppressants and 
chemotherapeutics, typically associated with severe side effects. For example, chemotherapeutic 
methotrexate is widely regarded as the gold standard of treatment, although its use is sometimes 
discontinued due to hepatic toxicity [126]. In addition to toxicity, this drug has an unpredictable 
efficacy profile, well tolerated and efficacious for certain patients, while ineffective for others.  
Recently, biologic agents aimed at interacting with specific cytokines have been introduced. 
These treatments are effective for some patients, but are associated with a drastically increased 
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risk of infection, requiring careful monitoring, and are known to have a high risk of infection in 
severe RA patients [127]. Furthermore, these therapies are extremely expensive, costing 
upwards of $30,000 annually.  
3.2. In vitro models for investigating CF and RA 
The first step in investigating efficacy of drug carrier systems is very often in vitro cell 
culture models. In vitro cell models allow for preliminary testing of a materials safety and 
efficacy without the extensive resources required for animal testing applications.  
Several options for RA in vitro models exist, including cell lines and primary cells isolated 
from tissue obtained from RA patients. Typically, cells used in the models are activated 
macrophages or fibroblasts, as these are the two cell types highly involved in regulating the 
pro/anti-inflammatory cytokine imbalance. While in vitro models are in general less predictive 
than in vivo models, they provide essential data regarding the effect of the compound in question 
on a simplified, more direct model of interest. Among in vitro models for RA, primary cells are 
generally considered more predictive than cell lines, and several studies have noted discrepancies 
in gene expression and protein secretion between cell lines and primary cells[128].  
 CF in vitro models are somewhat complicated, as this disease affects multiple organs and 
systems. For the work described here, a simple respiratory model was utilized. Specifically, 
airway epithelial monolayers with the CFTR mutation characteristic of CF airway cells was 
used throughout the CF in vitro experiments. Other airway in vitro models include use of sub-
mucosal gland (SMG) acini cells, and SMG acini/airway epithelial co-cultures. For the scope of 
the experiments presented, an airway epithelial model supplemented with a 
bacterial/mammalian co-culture was sufficient. This model will be discussed in depth in 
chapters six and seven. 
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3.3. Drug delivery systems for nucleic acids  
Viral vectors are typically thought of as the most efficient nucleic acid delivery agents due to 
a history of evolution aimed at maximal cell entry [129]. In addition to a high rate of infection, 
these vectors are able infect a wide variety of cell types. However, viral vectors are associated with 
major drawbacks, including viral induced immunogenicity, toxicity, mutation of the nucleic acid 
of interest with the viral DNA, and the potential for inactivation of the gene of interest due to 
recombination [97].  
Several successful colloidal nucleic acid delivery systems, particularly those formed from 
natural polymers are also being explored as alternative systems [130-132]. For instance, gelatin-
based nanoparticles were coated with DNA oligonucleotides with high loading efficiency [133]. 
Ionically cross-linked chitosan nanoparticles with the ability to entrap plasmid DNA were recently 
reported by Csaba et al. and were highly effective at transfecting cells in vitro and in vivo [134]. 
This supports literature claims stating that chitosan and chitosan-derivatives, such as quaternized 
chitosan, may be particularly advantageous in the delivery of nucleic acid-based therapeutics by 
providing biodegradable polymers with low cytotoxicity that reduces enzymatic degradation [8, 
131]. Although the cationic nature of chitosan, as well as other non-viral, polymeric vectors, 
facilitates binding of nucleic acids, the positive charge attracts anionic serum proteins. These 
proteins tag the carrier system for recognition by the reticuloendothelial system (RES) and lead to 
elimination from systemic circulation. This is a major problem, and must be addressed when 
designing drug carrier systems. Hydrophilic polymers such as poly (ethylene glycol) (PEG) are 
often introduced to avoid RES uptake through the formation a hydration layer that reduces 
extracellular interactions [135-137].  
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Despite wide usage in drug delivery applications, an increasing number of reports are 
suggesting that PEG, although widely regarded as non-immunogenic, is actually quite capable of 
inducing an immune response in both animal models and human patients particularly when 
administered repeatedly. For example, Semple et. al observed generation of PEG-reactive plasma 
immunoglobulin M (IgM) after dosing with PEG-liposomes in mice, as well as rapid clearance of 
the material from the animals circulation [138]. A recent study by Hamad and coworkers report 
concentration and molecular weight dependent activation of the complement system by PEG[139]. 
Complement activation is a cascade of proteins and signaling molecules that function in addition 
to antibodies to clear pathogenic material from the body. When combined with the antibody 
response, the complement system has potential substantially increase the immune response, 
especially in individuals who present PEG sensitivity. A recent study regarding the use of 
PEGylated liposomes for gene delivery showed although PEG modified carriers resulted in 
increased circulation time initially, after administration of a second dose, the ABC phenomenon 
was readily observed [140]. Therefore, it is suggested that the accelerated blood clearance (ABC) 
mechanism often seen in studies involving PEG and PEGylated materials can be attributed to an 
increased immune response[141].  
In addition to potential immunogenicity, it should be noted that PEG is a synthetic material, 
and therefore does not always exhibit good biodegradability.  To compensate for a lack of 
biodegradability, low molecule weight polymers are desired for use, as they may exhibit better 
urinary and/or hepatic clearance. However, low molecular weight PEG (<400 Da) is able to be 
metabolized by alcohol and aldehyde dehydrogenase, resulting in toxic by-products including 
diacid and hydroxyacid, which have been shown to lead to acidosis in human and animal 
studies[142].  
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Due to the lack of degradability and potential immunogenicity of PEG, in this study we use 
polysialic acid as an alternative [143, 144]. Preparation, drug loading, and characterization of 
polysialic acid-N-trimethyl chitosan (PSA-TMC) nanoparticles will be described in detail in 
chapter four.  
3.4. Goals and hypotheses 
   Based on the positive surface charge of the nanoparticles, nucleic acid oligonucleotides are 
hypothesized to have the ability to be incorporated with the nanoparticles for in vitro delivery. In 
addition to the ability to load negatively charged nucleic acids, the PSA-TMC delivery is 
advantageous over other polymeric drug delivery systems for applications in RA and CF 
treatment. These diseases are both characterized by inflammation and/or infection, as well as an 
overactive immune system. Therefore, a delivery system with a lack of cytotoxicity and 
immunogenicity is essential. Polysaccharides, such as PSA and chitosan are non-cytotoxic, non-
immunogenic, and can be degraded using mechanisms already in place in the human body, giving 
them several advantages over synthetic materials [6, 49]. The major hypotheses that have been 
investigated in this project are as follows: 
1. PSA-TMC nanoparticles are a non-immunogenic, biodegradable polysaccharide 
delivery system and can load oligonucleotides in a more safe and effective manner than 
existing transfection reagents.  
2. Using PSA-TMC to delivery an NF-κB decoy oligonucleotide will modulate the 
immune response and reduce inflammation in in vitro models of cystic fibrosis and 
rheumatoid arthritis, as listed below:  
i. IB3-1 epithelial cell cystic fibrosis 
ii. SW982 rheumatoid arthritis 
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iii. Primary synoviocyte rheumatoid arthritis 
iv. IB3-1/PA01 epithelial cell/bacterial co-culture 
These hypotheses were tested via a variety of characterization and in vitro cell culture 
experiments, as described in the following chapters.  
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4. Synthesis and characterization of PSA-TMC 
nanoparticles as a delivery system for ODN 
The polysaccharide based nanoparticle system PSA-TMC was initially developed in the 
Bader lab with the intention of loading DMARDs for the treatment of rheumatoid arthritis. In 
addition to showing DMARD loading capability, the particles proved to be non-cytotoxic, with 
components known to be biodegradable and non-immunogenic, resulting in a carrier system 
suitable for drug delivery applications in RA. The Bader lab has previously shown PSA-TMC 
loaded with DMARDs such as methotrexate and dexamethasone resulted in decreased 
inflammation in an RA in vitro model [145]. A brief collaboration resulted in the realization that 
aptamers, small nucleic acid sequences, could be effectively loaded into the particle matrix as 
well. This realization, combined with P.R.Wardwells weird fascination with NF-κB, led to the 
inception of the idea to use PSA-TMC nanoparticles loaded with transcription factor decoys 
against NF-κB in an attempt to modulate the immune response in diseases associated with 
inflammation. This chapter describes merits of PSA and TMC as nanocarrier components, as 
well as synthesis and characterization methods associated with production of the nanoparticles.  
4.1 Introduction 
To improve upon viral and cationic lipid transfection vectors, a number of investigators 
have begun to explore alternative carrier systems, including microspheres and nanoparticles, for 
delivery of nucleic acids [4, 130, 146-148]. These systems are often viewed as being less 
efficient in terms of nucleic acid cellular penetration, but this potential concern becomes 
secondary when considered in conjunction with the ease of production, high loading capacity, 
and a lack of immune response [133, 134]. 
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 Polysaccharides have emerged in recent years as highly desirable materials for 
incorporation into drug delivery systems. Characteristics including structural diversity, a high 
potential for modification due to many reactive groups, general aqueous solubility, as well as (in 
some cases) innate bioactivity contribute to the interest in polysaccharides in drug delivery 
systems. Polysialic acid (PSA) is a hydrophilic natural polymer which, similar to polyethylene 
glycol (PEG), facilitates formation of a water layer around colloidal particles. However, as 
discussed in chapter three, PEG has some serious drawbacks which make it a questionable choice 
for inclusion in drug carrier systems for diseases characterized by excessive inflammation. Unlike 
PEG, however, PSA has no known receptors in the human body, contributing to a lack of 
immunogenicity and toxicity, two factors of key importance in drug delivery applications aimed 
at immunomodulation. PSA was first described for drug delivery by Gregoradis as a means of 
enhancing circulatory stability and half-life of therapeutics through conjugation [137]. The Bader 
lab recently reported nanoparticles formed by ionic complexation of PSA and N-trimethyl 
Fig. 13: Synthesis scheme of ionic complexation of PSA-TMC nanoparticles coated with 
NF-κB Decoy ODN. TMC is positively charged, PSA is negatively charged, and the two 
polymers interact in the presence of a polyanionic cross-linker via ionic gelation to form 
nanoparticles. 
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chitosan (TMC) with a small size (~100 nm), positive surface charge, and a low degree of 
cytotoxicity[149].  
Chitosan has been a material of interest for nucleic acid delivery for some time now. The 
biocompatibility, lack of toxicity, relatively low cost and general cationic, easily modifiable nature 
make chitosan an attractive choice for gene delivery applications [150]. However, clinical success 
of initial chitosan/DNA based polyplexes was limited by low transfection efficiencies, and the high 
dependence of environmental factors (especially pH) on biological function [151]. These nucleic 
acid delivery systems are often associated with aggregation, and rapid clearance. Recently, many 
researchers have reported modifications of chitosan with polymers such as PEG or PEI, generating 
graft-copolymers for nucleic acid nanocarrier systems with the goal of increasing stability and 
transfection efficiency [151-154]. While moderate success was seen with these formulations, the 
use of potentially cytotoxic materials makes these alternatives an undesirable choice for 
applications aimed at treating excessive inflammation.  
An alternative to control the functionality of chitosan across pH ranges is to use TMC, a 
derivative of chitosan modified via methylation, to improve solubility and potentially transfection 
efficiency [155]. Incorporation of PSA, a negatively charged, highly hydrophilic material, yields 
particles with a smaller size and greater stability, improving upon particles made of chitosan or 
TMC and DNA alone. Zhang et al. recently reported that ionic complexation of PSA with TMC 
yields a non-cytotoxic nanoparticle carrier system with a size (~100 nm) and positive surface 
charge. A synthesis scheme depicting formation of particles via ionic complexation of PSA and 
TMC and subsequent ODN coating is shown in Fig. 13. Although this system was initially 
developed with the aim of improving RA treatment, the size, stability, and positive surface charge 
are amenable to ODN delivery [156]. PSA serves as a natural polymer for enhancing the 
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circulatory stability and facilitating passive accumulation of associated therapeutics within 
diseased tissue that is characterized by leaky vasculature, as occurs with RA. In the physiological 
environment, PSA reduces undesirable protein and cell interactions through the formation of a 
protective envelope of water molecules [135-137]. PSA thus provides a biodegradable, non-
immunogenic alternative to synthetic PEG.  
Although Gregoriadis et al. pioneered using PSA conjugation as a method of enhancing the 
circulatory stability of associated therapeutics [135-137], our group is the first to use PSA as the 
basis of nanocarrier systems [7, 156-158]. Relative to other anionic polysaccharides, electrostatic 
interaction of the positively charged ammonium groups of TMC with the negatively charged 
carboxylic acid groups along the highly flexible PSA backbone yields intermolecular complexes 
of a small size [159-161]. The cationic, quaternized chitosan also facilitates adhesion of negatively 
charged nucleic acids [162]. The PSA-TMC nanoparticles, therefore, have the potential to serve 
as ideal, biodegradable, non-immunogenic carrier systems for nucleic acid-based therapeutics.  
4.2 Materials and methods 
4.2.1 Materials 
Polysialic acid (colominic acid, PSA) was obtained from Nacalai USA, Inc. (San Diego, 
CA, USA). N-trimethyl chitosan (TMC) was produced via quaternization of chitosan (MW 100 
Da-300 Da) obtained from Acros Organics (New Jersey, USA), as described previously by 
Sieval et. Al[163]. Sodium tripolyphosphate (TPP) was purchased from Acros Organics, New 
Jersey, USA. An NF-κB decoy oligonucleotide (ODN) kit containing NF-κB decoy ODN (5’ 
CCT TGA AGG GAT TCC CTT CC 3’) and a scrambled ODN (5’ TTG CCG TAC CTG ACT 
TAG CC 3’) was purchased from CosmoBio (Tokyo, Japan). Methotrexate (MTX) was 
obtained from Enzo Life Sciences (New York, USA) 
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4.2.2 PSA-TMC-ODN preparation 
ODN coated PSA-TMC nanoparticles were prepared as previously described [145]. 
Briefly, 6.4 mg of TMC (55% quaternization) were dissolved in 3.0 ml of 0.3% acetic acid in a 
glass vial. Meanwhile, 3.2 mg of PSA and 1.0 mg of TPP were dissolved in 2.0 ml of DI H2O. 
When MTX was incorporated into the particles, 2.4 mg MTX was added to the PSA/TPP 
solution. The latter solution was sonicated for 10 minutes and then added drop-wise to the TMC 
solution with stirring. Stirring was continued at room temperature for 20 minutes. At this time, 
10 µg ODN were added to the nanoparticle suspension. Stirring was continued for an additional 
10 minutes to ensure uniform electrostatic adhesion of ODN to the nanoparticle surface, as well 
as complete dispersion. Upon completion of stirring, centrifugation at 3000 RPM for 15 minutes 
yielded a pellet of ODN-coated PSA-TMC nanoparticles.  
4.2.3 PSA-TMC-ODN characterization  
Nanoparticle size, zeta potential, and polydispersity index were determined using a 
Malvern Zetasizer NanoZS90 (Malvern Instruments, Malvern UK). Following particle formation 
and centrifugation, nanoparticles were resuspended at a concentration of 2 mg/ml in DI water 
and filtered through a 0.45 µM syringe filter. Samples were loaded into cuvettes or capillary cells 
for measurements of size or zeta potential, respectively, taken at 25 °C.  
4.2.4 Determination of ODN and MTX loading 
A rhodamine tagged ODN (5’ (TAMRA-X) (C6-NH) CCT TGA AGG GAT TTC CCT 
CC 3’) was used to assess ODN loading.  ODN-coated PSA-TMC nanoparticles were prepared; 
and, after centrifugation, the supernatant was collected for quantitative analysis of unbound 
ODN.  Supernatant fluorescence values were determined using a synergy 2 multimode plate 
reader (BioTek Instruments, Winooski VT). Total amount of ODN in the supernatant was 
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determined from the supernatant fluorescence readings compared to a standard curve of 
fluorescent ODN, and the following equations were used to determine loading efficiency (LE) 
and loading capacity (LC): 
                𝐿𝐸 = (
𝑀𝑂𝐷𝑁 𝑎𝑑𝑑𝑒𝑑−𝑀𝑂𝐷𝑁 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡
𝑀𝑂𝐷𝑁 𝑎𝑑𝑑𝑒𝑑
) 𝑥 100                                          (1)                                                                                                                                                                                                                                                                                                                              
                    𝐿𝐶 =
𝑀𝑂𝐷𝑁 𝑎𝑑𝑑𝑒𝑑−𝑀𝑂𝐷𝑁 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡
𝑀𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
                                                    (2) 
where MODN added is the mass of ODN added to the initial nanoparticle formulation, Msupernatant 
is the mass of ODN in the supernatant, as determined by fluorescence analysis, and Mnanoparticles is 
the mass of the nanoparticles used for ODN loading.   
HPLC was used to determine the amount of MTX loaded into ODN coated nanoparticles. 
After nanoparticles were pelleted via centrifugation, supernatant samples were saved and 
analyzed using a Prominence Ultrafast Liquid Chromatography System (UFLC, Shimadzu 
Instruments, Japan). Samples were run using a 93:7 (v/v) mixture of 50 mM ammonium acetate 
and acetonitrile mobile phase at a flow rate of 0.75 ml/min with a 100 µL injection volume. The 
detection wavelength used was 210 nm. To determine the amount of MTX present based on peak 
area, a calibration curve of 8 known concentrations (50 µg/ml to 0.39 µg/ml) of MTX was 
constructed. PeakFit 4.2 software was used to analyze peak area. 
4.2.5 Analysis of protective effect of PSA-TMC on ODN 
 PSA-TMC and DNA degradation was assessed using an adapted protocol from Mao et. al. 10 
mg PSA-TMC-ODN (equivalent of 1 µg ODN/mg PSA-TMC, designated NPODN) was 
prepared with ODN coated on the surface, and encapsulated (NPODNE). Bare PSA-TMC 
(designated NP) was also prepared. After centrifugation, all particles were resuspended in 0.5 ml 
Millipore H20 at a concentration of 2 mg PSA/TMC and 2 µg ODN per 100 µl. 3 100 µl aliquots 
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were prepared from each 500 µl nanoparticle suspensions. ODN, NP, NPODN, and NPODNE 
were incubated at 37 degrees C for 15 minutes with 0.0, 0.4 or 4.0 µg DNAse 1 for 15 minutes. 
The reaction was stopped by adding 100 µl of 10 mM iodoacetic acid for a final iodoacetic acid 
concentration of 5 mM. Digestion was then carried out with lysozyme and chitosanase. 
Lysozyme was added at a concentration of 40 U/100 µl, and chitosanase was added at a 
concentration of 0.1 U/100 µl to all samples digested previously with DNAse1. The control 
samples were not degraded with lysozyme or chitosanase. Digestion continued for 4 hours at 37 
°C. After 4 hours of enzymatic digestion, samples were removed from heat and placed on ice 
immediately to stop activity. Samples were either frozen or run on a 20% Polyacrylamide gel. 
All gels were run at 200 mV for 40-50 minutes. The fastest running band on the loading buffer is 
said to be equivalent of about a 20 bp DNA sequence. 
4.3 Results and discussion 
4.3.1 Nanoparticle characterization 
As expected based on these prior studies, NP possessed a size of close to 100 nm (115 
nm) and a positive zeta potential (37 mV), while NP-ODN nanoparticles possessed a 
significantly larger size with a diameter of 159 ± 15 nm and decrease in surface charge to 23 mV 
[145, 152]. Furthermore, NP-ODN loaded with MTX led to another slight size increase, 
insignificantly larger than NP-ODN alone, with a diameter of 184 ± 5.6 nm while maintaining a  
 Size (nm) Zeta Potential (mV) Polydispersity index 
NP 115 ± 5.6 37 ± 6.3 0.10 
NP-ODN 166 ± 4 23 ± 6.5 0.09 
NP-ODN-MTX 184 ± 5 33 ± 6.5 0.09 
Table 2: Characterization data associated with PSA-TMC NP formulations 
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positive zeta potential of approximately 33 ± 6.5 mV. All nanoparticle formulations possessed 
size between 100 and 200 nm, favorable for evading the reticulondothelial system (RES) in 
applications for drug delivery [156]. Size, zeta potential, and polydispersity index of the three 
different nanoparticle formulations are portrayed in table 4.1. 
 Systematic analysis of nanoparticle formation via ionic complexation has been 
investigated previously [164, 165]. Consensus of these studies suggest that initiation of particle 
formation as well as particle size is highly influenced by charge ratio. A charge ratio of 
approximately 1:1 (+ :-) is essential for initiation of particle formation, regardless of charge 
strength. Dragan et. al illustrates this charge dependent phenomenon by varying charge ratios 
and measuring suspension turbidity. At a ratio of 1:1, a shift in turbidity occurs, indicating 
particle formation [164]. The PSA-TMC nanoparticle generation described above contains 
polymer amounts with the exact charge ratios recommended for complex formation. Chitosan to 
TMC modification results in polymer with approximately 55% modification, or a 55% positive 
charge. Using a TMC:PSA ratio of 2:1 results in a charge ratio of approximately 1:1. The ideal 
charge ratio combined with the flexibility of PSA, as described in section 4.1 results in 
generation of stable, reproducible particles with sizes ranging from ~100 nm (unloaded) to ~200 
nm (loaded with MTX and ODN).   
4.3.2 ODN and MTX loading 
The PSA-TMC nanoparticles were successfully coated with ODN with a loading 
efficiency and loading capacity of 76.6 ± 8.6% and 0.77 ± 0.09 µg/mg nanoparticles, 
respectively. HPLC was performed to determine the amount of MTX loaded within the NP-
ODN-MTX nanoparticles. Loading capacity and loading efficiency values of .20 mg MTX/mg 
nanoparticle and 86.7 %, respectively were obtained. 
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4.3.3 Protective effect of PSA-TMC on ODN 
Enzymatic degradation of ODN coated PSA-TMC, ODN encapsulated PSA-TMC, and 
TMC alone was performed. Based on enzymes present in vivo, DNAse1, lysozyme, and 
chitosanase enzymes were used to test stability. Despite several attempts, and a very high gel 
percentage, DNA fragments were not detectable. In addition, different post-run stains, including 
silver stain, methylene blue, and ethidium bromide were used in an effort to detect bands of 
DNA. A summary of different staining methods can be found in table 4-2.  
Attempt, 20% Gel Stain Result 
1 Silver Quest (silver stain) No band visualization, not even the 
ladder. This was not an appropriate 
stain to use. 
2 Methylene Blue Ladder visualization, no bands from 
any of the samples 
3 Ethidium Bromide No ladder visualization, saw bands 
from the ODN samples after 15 
minute stain incubation, but after 2.5 
hour stain incubation, saw nothing. 
 Potential alternatives to detecting DNA post-degradation include PCR amplification prior 
to running the gel. However, without knowing the exact degradation pattern, this would require 
multiple primers, and in general turn into a larger scale study than originally anticipated. This 
will be a continued investigation, as it provides an excellent introduction to continuing the 
project for a potential new student.   
4.4 Conclusions 
Initial preparation of ODN loaded PSA-TMC was performed by incorporating the nucleic 
acids directly into the polymer network. While this resulted in nanoparticles of desired size and 
Table 3: A summary of gel staining attempts to visualize enzymatically digested ODN, and 
the results 
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zeta potentials, the addition of negatively charged materials to the polymer matrix appears to 
have increased the particle stability beyond what was desired. Therefore, the nucleic acid release 
from the nanoparticles was extremely slow, and not conducive to the applications being 
investigated here. To rectify this, nucleic acids were instead coated on the surface of the 
nanoparticle, as the positively charged particle surface will attract and adhere the ODN’s due to 
electrostatic interactions. As expected, coating the surface with ODN led to acceptable loading 
levels, with sufficient payload release. 
PSA-TMC nanoparticles showed high loading capability of MTX, as expected based on 
previous studies, and ODN. Upon determination of successful synthesis and loading of PSA-
TMC nanoparticles, in vitro studies were carried out to determine potential applications of these 
materials. Previous studies as well as the innate properties of the materials used to develop the 
nanoparticles have confirmed a lack of toxicity toward rheumatoid arthritis cell line, however 
toxicity was investigated for other cell lines used in the studies. These cytotoxicity and efficacy 
in vitro studies are described extensively in the following chapters.  
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5. Modulation of the immune response via NF-kB decoy 
ODN coated nanoparticles in in vitro models of rheumatoid 
arthritis 
Abstract 
The transcription factor nuclear factor-kappa B (NF-κB) is highly involved in regulation of a 
number of cellular processes, including production of inflammatory mediators. Thus, this 
transcription factor plays a role in pathology of many diseases, including rheumatoid arthritis, an 
autoimmune disease hallmarked by an imbalance of pro and anti-inflammatory cytokines. Small 
nucleic acids with sequences that mimic the native binding site of NF-κB have been proposed as 
treatment options for RA; however due to low cellular penetration and a high degree of 
instability, clinical applications of these therapeutics have been limited. Here, we describe the 
use of N-trimethyl chitosan-polysialic acid (PSA-TMC) nanoparticles coated with NF-κB decoy 
ODNs (PSA-TMC-ODN) as a method to enhance the stability of the nucleic acids and facilitate 
increased cellular penetration. In addition to decoy ODN, PSA-TMC nanoparticles were loaded 
with RA therapeutic methotrexate (MTX), to assess the anti-inflammatory efficacy of a 
combination therapy approach. Two difference in vitro models, a cell line based model as well as 
a primary RA cell model were used to investigate anti-inflammatory activity. One way ANOVA 
followed by Holm-Sidak stepdown comparisons was used to determine statistical significance. In 
general, free ODN did not significantly affect secretion of pro-inflammatory cytokines 
interleukin-6 (IL-6) and interleukin-8, (IL-8) while free MTX had variable efficacy. However, 
PSA-TMC-ODN and PSA-TMC-ODN-MTX resulted in significant decreases in the 
60 
 
inflammatory mediators IL-6 and IL-8 in both cell models. In addition, PSA-TMC exhibited 
sufficient cellular uptake, as observed through fluorescence microscopy.  
These results support our previous findings that PSA-TMC nanoparticles are an effective 
delivery vehicle for small nucleic acids, and effectively alter the pro-inflammatory state 
characteristic of RA.  
*This chapter has been adapted from an original manuscript by P.R. Wardwell submitted to the 
journal Arthritis Research and Therapy 
 
5.1 Introduction 
Rheumatoid arthritis is an autoimmune disease characterized by inflammation of the synovial 
tissue of joints. Over time, the infiltration of immune cells to the synovial lining leads to 
hyperplasia, increased vascular growth, and formation of a tumor like tissue known as the 
pannus [166]. The physiology of a chronic inflammatory state eventually results in cartilage 
degradation and bone resorption. An imbalance of pro- and anti-inflammatory cytokines 
contribute to the state of chronic inflammation. Briefly, the levels of anti-inflammatory 
cytokines (Interleukin (IL)-4, IL-10, and IL-13) present in the synovium are too low to combat 
the effects of pro-inflammatory cytokines (tissue necrosis factor-α (TNF-α), IL-1, IL-6, and IL-
8) [124].  Of the cells present in the RA synovial lining, ‘macrophage-like’ cells and activated 
synovial fibroblasts are accepted as the primary mediators of the pro/anti-inflammatory 
imbalance [167, 168].  
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NF-κB is a transcription factor involved in the regulation of a variety of cellular processes, 
including growth, apoptosis, and inflammatory and immune responses [108]. NF-κB dependent 
gene expression is known to play a critical role in the observed cytokine imbalance, as well as 
contribute to increased 
inflammation in rheumatoid 
arthritis [110, 169]. Under 
normal conditions, NF-κB is 
sequestered in the cytoplasm 
by means of a bound inhibitor 
known as IkB (inhibitor of κB). 
External stimulation from 
inflammatory mediators, 
including IL-1β, leads to a 
signaling cascade that results in 
phosphorylation of the 
inhibitor, followed by 
dissociation of the NF-κB/IκB 
complex and subsequent 
nuclear translocation of NF-
kB. Once inside the nucleus, NF-kB initiates transcription of pro-inflammatory cytokines, 
including IL-6 and IL-8, two cytokines highly involved in regulating inflammation in RA. IL-6 
and IL-8 both possess NF-κB binding sites on their promotor regions, indicating they are highly 
regulated by NF-κB [170]. Transcription factor decoy oligonucleotides (ODNs) have the 
Fig. 14. An illustration of the NF-κβ pathway activation in 
a RA synovial fibroblast cell. Pro-inflammatory cytokines, 
including IL-1β activate the cell signaling pathway 
associated with NF-κβ, including activation of IκK, 
phosphorylation and inactivation of Iκβ, and translocation 
of NF-κβ to the nucleus. NF-κβ decoy ODN’s can prevent 
translocation of the transcription factor, as well as 
subsequent transcription of NF-κβ dependent genes. 
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potential to reduce inflammation in RA by binding to NF-kB in the cytoplasm, preventing 
nuclear translocation, and inhibiting NF-κB mediated transcription of pro-inflammatory 
proteins. The mechanism of decoy ODN is illustrated in Fig. 14.  
Transcription factor decoy ODNs mimic the native DNA binding site of the transcription 
factor, but are only ~ 20 base pairs long, and do not encode any genes. NF-kB decoy ODNs 
have been proposed as treatment for RA previously [171]. However, despite promising potential 
for treatment, applications have been limited by low cellular penetration and a lack of stability 
of the nucleotides, which combined result in low overall bioavailability [172, 173]. As 
mentioned in the introduction section, methyl phosphonate or phosphorothioate chemical 
modifications are often applied to the nucleotide backbones as a means to overcome stability 
problems; however although  these modifications enhance stability, they do not necessarily lead 
to increased delivery efficiency, resulting in the need for a high dose and frequently repeated 
delivery [2]. Nucleic acids containing these modifications have been shown to have a 
concentration dependent toxicity toward mammalian cells, therefore this is not a sustainable 
method for delivery[3, 4]. 
As discussed in chapter two, methods such as viral vectors, cationic lipid formulations and 
more recently, cationic polymer formulations, exist to overcome the barriers to nucleic acid 
delivery. To reiterate nucleic acid drug delivery system requirements as initially stated in 
chapter one, drug delivery systems for nucleic acids must have attributes including 
biocompatibility and biodegradability, reticuloendothelial system (RES) avoidance, non-
immunogenicity, cellular uptake capability, and cell or tissue specificity [5]. In terms of these 
attributes, viral vectors are associated with major drawbacks, including viral induced 
immunogenicity, toxicity, mutation of the nucleic acid of interest with the viral DNA, and the 
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potential for inactivation of the gene of interest due to recombination [97]. Cationic lipid based 
Lipofectamine reagents, marketed by Life Technologies®, claim of increased efficiency over 
other available reagents and have become the most referenced lipid based transfection reagent. 
However, in addition to marked toxicity exhibited by these reagents in cell lines, these 
compounds are associated with metabolism by the liver in vivo, resulting in degradation of the 
nucleic acid payload [104, 105].  
Due to the drawbacks of viral vectors and cationic lipid delivery methods, cationic polymers 
have been the focus of recent research as an alternative for nucleic acid delivery. One of the 
most widely used polymers in nucleic acid delivery is poly (ethyleneimine) (PEI). However, 
PEI exhibits considerable toxicity toward a variety of mammalian cells [106] [107]. Delivery 
systems for RA, where the ultimate goal is to reduce inflammation, require materials that do not 
contribute to inflammation or the immune response and that exhibit low levels of toxicity. 
Therefore, an alternative delivery method to viral vectors, cationic lipids and synthetic cationic 
polymers is needed. 
A polysaccharide based system containing two natural polymers, N-trimethyl chitosan 
(TMC) and polysialic acid (PSA) has previously been described. This nanoparticle system is 
non-cytotoxic, non-immunogenic, and has been shown to effectively deliver encapsulated 
disease modifying anti-rheumatic drugs (DMARDs) and surface-coated with NF-kB decoy 
ODNs when applied to in vitro models of rheumatoid arthritis and cystic fibrosis, respectively 
[145, 174]. In this chapter, the use of PSA-TMC nanoparticles as a delivery system to combine 
treatment of a DMARD, methotrexate, and NF-κB decoy ODN is reported. While combination 
therapies have been reported before, particularly NF-κB inhibitors, to the best of the author’s 
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knowledge, this is the first report of combining DMARD methotrexate with a transcription 
factor decoy NF-κB inhibitor. 
5.2 Materials and Methods 
5.2.1 Materials 
Polysialic acid (colominic acid, PSA) was obtained from Nacalai USA, Inc. (San Diego, CA, 
USA). N-trimethyl chitosan (TMC) was produced via quaternization of chitosan (MW 100 Da-
300 Da) obtained from Acros Organics (New Jersey, USA), as described previously by Sieval et. 
Al[163]. Sodium tripolyphosphate (TPP) was purchased from Acros Organics, New Jersey, 
USA. An NF-κB decoy oligonucleotide (ODN) kit containing NF-κB decoy ODN (5’ CCT TGA 
AGG GAT TCC CTT CC 3’) and a scrambled ODN (5’ TTG CCG TAC CTG ACT TAG CC 3’) 
was purchased from CosmoBio (Tokyo, Japan). Recombinant human interleukin-1β was 
obtained from R and D systems (Minneapolis, MN). Methotrexate (MTX) was purchased from 
Enzo Life Sciences (Rochester, NY). Alexa Fluor 488 succinimidyl ester was purchased from 
Invitrogen/Life Technologies (Grand Island, NY). 
5.2.2 Cell culture 
SW982 cells were obtained from ATCC (Manassas, VA, USA) and grown in Dulbecco’s 
Modified Eagles Medium (DMEM, Fisher Scientific, USA) supplemented with 10% Fetal 
Bovine Serum (FBS, Atlanta Biologicals, Atlanta, GA) until confluent.  Primary RA cells were 
isolated from synovial tissue obtained from two Caucasian RA patients, both women between the 
ages of 50 and 59. The tissue samples were obtained by Dr. Timothy Damron at Community 
General Hospital (Syracuse, NY) following written and informed consent by each patient, as 
required by an Institutional Review Board–approved protocol. Tissue was isolated following a 
protocol outlined by Zimmerman [175]. Briefly, the synovial tissue was minced finely and 
65 
 
incubated at 37° with 0.1% Trypsin (Invitrogen, Carlsbad, CA) in PBS for 30 minutes. Tissue 
was then digested for two hours in DMEM with 0.1% Collagenase P. After digestion, tissue was 
filtered through a 100 µM filter. The resultant solution was centrifuged, and the pelleted cells 
were resuspended in DMEM with 10% FBS, placed in a T-75 flask, and cultured at 37°C with 
5% CO2. After three passages, the cells were stained with CD44-FITCmAB (Santa Cruz 
Biotechnology, Santa Cruz CA) to confirm fibroblast cells. To supplement the two sets of 
primary cells obtained through synovial tissue isolation, Human Fibroblast Like Synoviocytes 
(HFLS, lot numbers 2884 and 2956, female Caucasian) were obtained from Cell Applications 
(CA, USA) and cultured in DMEM with 10% FBS at 37°C with 5% CO2. 
5.2.3 Nanoparticle preparation and characterization 
ODN coated PSA-TMC nanoparticles were prepared as previously described and detailed in 
chapter four [145]. Nanoparticle size, zeta potential, and polydispersity index were determined 
using a Malvern Zetasizer NanoZS90 (Malvern Instruments, Malvern UK). Following 
centrifugation, nanoparticles were resuspended at a concentration of 2 mg/ml in DI water and 
filtered through a 0.45 µM syringe filter. Samples were loaded into cuvettes or capillary cells for 
measurements at 25 °C.  
5.2.4 In vitro efficacy of ODN-coated PSA-TMC nanoparticles 
SW982 cells or primary RASF cells were plated on 24 well plates at a density of 20,000 
cells/well. In addition to ODN coated nanoparticles (NP-ODN), bare nanoparticles (NP), MTX 
loaded nanoparticles (NP-MTX), ODN coated MTX loaded nanoparticles (NP-MTX-ODN) and 
nanoparticles coated with a scrambled oligonucleotide (NP-SCO) were prepared. As a control, 
MTX alone was prepared at a concentration of 1.0 mg/ml DMEM media. After centrifugation, 
all nanoparticles were resuspended in serum free DMEM at a concentration of 1.0 mg/ml. 500 µl 
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of each treatment group was added to the 24 well plate in duplicate as follows: 1. Media alone 
(control), 2. ODN alone, 3. NP-ODN, 4. NP, 5. NP-SCO, 6. NP-MTX, 7. NP-ODN-MTX, and 8. 
MTX alone.  The complexes were removed and media supplemented with FBS was replaced 
after 4 hours to allow for normal growth conditions. 24 hours after initial complex addition, 
inflammation was induced with the addition of 1.0 ng/ml of interleukin 1β (IL-1β). This 
concentration has been shown to increase levels of IL-6 and IL-8 when administered to SW982 
cells [176].After incubation at 37°C for an additional 24 or 48 hours,, supernatant samples were 
collected and stored at -80°C for analysis of IL-6 and IL-8.  
5.2.5 Quantitative analysis of inflammatory cytokines 
ELISA kits for IL-6 and IL-8 were purchased from Peprotech (Rocky Hill, NJ) and run 
according for manufacturer instructions. Samples were run in duplicate, and each experiment 
was repeated independently at least 3 times. 
5.2.6 In vitro cellular uptake 
To examine internalization of the nanoparticles, cellular uptake experiments were performed. 
Prior to nanoparticle synthesis, TMC was tagged with Alexa-Fluor 488® carboxylic acid, 
succinimidyl ester, mixed isomers in DMSO (1 mg/mL), (Invitrogen, Grand Island, NY). 25 mg 
of TMC were dissolved in 4 ml of 0.1 M sodium bicarbonate buffer (pH 8.3). 500 µl of AF 488 
dye were added, and the solution was stirred for 1 hour at room temperature. Upon completion of 
stirring, the resultant material was dialyzed for 48 hours against water to ensure removal of un-
reacted dye. In addition, the amount of TMC used has an excess of reactive amine groups 
relative to amount of Alexa Fluor 488, therefore the amount of unreacted dye was expected to be 
negligible. H1 NMR confirmed dye conjugation. Cells were plated on lysine coated glass bottom 
dishes (Mattek Corp, Ashland, MA) at a density of 100,000 cells per dish two days prior to 
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scheduled imaging to allow for adherence and confluence. On the day of imaging, sterile filtered 
NP were administered to the plated cells at a concentration of 1 mg/ml. Complexes were 
incubated with the cells for 45 minutes at 37°C prior to removal. The cells were washed three 
times with 1X PBS immediately prior to imaging, and imaged using a Nikon Eclipse Ti inverted 
microscope.  
5.2.7 Statistical analysis 
IL-6 and IL-8 protein levels were expressed relative to an untreated, stimulated control group, 
with all data presented as mean ± standard deviation for all groups (N≥3). One-way ANOVA 
followed by Holm-Sidak testing for multiple comparisons was performed to compare IL-6 and 
IL-8 protein secretion following treatment and inflammatory stimulation. All statistical tests 
were conducted with an alpha value of 0.05. 
5.3 Results 
5.3.1 Effect of ODN and MTX loaded NP on IL-6 and IL-8 secretion in RA in vitro models 
To initially determine efficacy of NF-κB decoy ODN and MTX loaded NP, the SW982 cell 
line was used as a model of RA. The SW982 cell line has been shown to mimic activated RA 
synovial fibroblast cells in regards to the expression of inflammatory mediators, particularly 
when stimulated in 1 ng/ml IL-1β[177]. We have previously conducted cytotoxicity studies of 
PSA-TMC NP formulations and concluded NP, as well as NP-ODN, NP-MTX, and MTX alone 
do not impact cellular proliferation at low concentrations and are, therefore, appropriate for this 
study [145, 174].  
To assess the bioactivity of PSA-TMC NP coated with the NF-κB decoy ODN and/or loaded 
with MTX, the secretion of two potent inflammatory mediators, IL-6 and IL-8, by SW982 cells 
were investigated. Both of these pro-inflammatory mediators are directly influenced by NF-κB 
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and play a major role in the inflammatory response in RA. IL-6 is a multifunctional cytokine, 
with the ability to regulate the immune response, inflammation, and hematopoiesis and plays a 
crucial role in RA pathogenesis[178]. IL-8 was chosen as a representative chemokine and is 
responsible for recruiting immune cells to the synovium and contributing to the tumor-like 
pannus tissue. In addition, IL-8 is involved in up-regulation of inflammation via paracrine 
signaling mechanisms in the RA synovium [179].  The mechanism of action of MTX in RA 
treatment and inflammatory activity is currently unresolved; however, the drug is believed to 
interfere with cell folate metabolism. Furthermore, several reports suggest MTX acts on NF-κB 
as an inhibitor[180]. We explored co-administration of NF-κB decoy ODN and MTX to observe 
any potential synergistic activity. IL-6 and IL-8 levels were examined in response to treatment 
with NP-ODN, NP-MTX, NP-ODN-MTX, ODN alone, and MTX alone using immunoassays. 
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The IL-6 secretion profile in response to different treatment groups is shown in Fig. 15 In 
general, we were interested in the IL-6 response of cells subjected to the different treatment 
groups in comparison to untreated control cells and in comparison to cells treated with ODN 
alone. At 24 hours (Fig. 15A), cells treated with NP-ODN-MTX displayed a significant 
reduction of IL-6 relative to untreated control cells. A decrease in IL-6 levels in comparison to 
untreated control cells was also observed following treatment with NP-ODN; however, this 
reduction was not great enough to be significant. At 48 hours (Fig. 15B), a significant decrease 
relative to both untreated control cells and cells administered ODN alone was observed 
following treatment with NP-MTX and NP-ODN-MTX. NP-ODN displayed trends at 48 hours 
similar to those at 24. This treatment resulted in a decrease in IL-6 levels in comparison to both 
Fig. 15. ELISA was performed to determine levels of IL-6 secretion by SW982 cell line RA 
model cells, after treatment with ODN alone (ODN), NP coated with ODN (NP-ODN), NP 
loaded with methotrexate (NP-MTX), NP loaded with methotrexate and ODN (NP-ODN-
MTX), and MTX alone (MTX) and stimulation with IL-1B at 24 (A) and 48 (B) hours. Results 
are expressed as fold changes of IL-6 levels relative to an untreated control, shown as a solid 
line at 1. One way ANOVA followed by Holm-Sidak multiple comparisons testing was used to 
determine the impact of treatment on IL-6 secretion. * Represents a significant difference from 
the control, while † represents significant difference from ODN alone. All data is presented as 
mean ± SD (N=3). 
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untreated control cells and ODN alone; however, the decrease was not great enough to be 
significantly different.  
The IL-8 secretion profile from SW982 cells in response to treatment with different 
nanoparticle formulations is portrayed in Fig. 16. After 24 hours (Fig. 16A), NP-ODN-MTX 
resulted in a significant decrease in IL-8 levels compared to ODN administered alone. While the 
level of IL-8 in response to NP-ODN-MTX treatment was lower than the untreated control, the 
difference was not significant. At 48 hours, (Fig. 16B) multiple significant decreases in IL-8 
levels were observed. Cells treated with NP-ODN, NP-MTX, NP-ODN-MTX, and MTX alone 
all had IL-8 levels significantly lower than the untreated control cells and cells treated with ODN 
alone.  
Fig. 16. ELISA was performed to determine levels of IL-8 secretion by SW982 cell line RA 
model cells, after treatment with ODN alone (ODN), NP coated with ODN (NP-ODN), NP 
loaded with methotrexate (NP-MTX), NP loaded with methotrexate and ODN (NP-ODN-
MTX), and MTX alone (MTX) and stimulation with IL-1B at 24 (A) and 48 (B) hours. 
Results are expressed as fold changes of IL-8 levels relative to an untreated control, shown 
as a solid line at 1. One way ANOVA followed by Holm-Sidak multiple comparisons testing 
was used to determine the impact of treatment on IL-8 secretion. * represents a significant 
difference from the control, while † represents significant difference from ODN alone. All 
data is presented as mean ± SD (N=3). 
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These results suggest that PSA-TMC NP can be used to deliver decoy ODN and MTX, alone 
and simultaneously, to activated RA synovial fibroblasts. To further validate the ability of PSA-
TMC nanoparticles to serve as an effective treatment strategy for RA, in vitro experiments were 
also conducted with primary cells. Previous reports have noted discrepancies in cytokine 
production between cell line models and primary RASF cells [128]. Furthermore, a literature 
search revealed that immortalized cells, such as SW982, constitutively express the NF-κB 
pathway, indicating that they may be more susceptible to NF-κB interference than primary RASF 
cells [181].  
Primary RASF cell cytokine secretion was investigated following treatment with ODN, NP-
ODN, NP-MTX, NP-ODN-MTX and MTX. At 24 hours (Fig. 17A), a significant reduction in 
Fig. 17. ELISA was performed to determine levels of IL-6 secretion by primary RA synovial 
fibroblast cells, after treatment with ODN alone (ODN), NP coated with ODN (NP-ODN), 
NP loaded with methotrexate (NP-MTX), NP loaded with methotrexate and ODN (NP-ODN-
MTX), and MTX alone (MTX) and stimulation with IL-1B at 24 (A) and 48 (B) hours. 
Results are expressed as fold changes of IL-6 levels relative to an untreated control, shown as 
a solid line at 1. One way ANOVA followed by Holm-Sidak multiple comparisons testing 
was used to determine the impact of treatment on IL-6 secretion. * represents a significant 
difference from the control, while † represents significant difference from ODN alone. All 
data is presented as mean ± SD (N=4). 
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IL-6 secretion by the primary cells was observed in response to NP-ODN and NP-ODN-MTX in 
comparison to untreated control cells, as well as cells administered ODN  alone. While cells 
treated with NP-MTX and MTX alone experienced a decrease in levels of IL-6, the decrease was 
not great enough to be considered significant. A lack of significant reduction of IL-6 secretion in 
response the NP-MTX and MTX alone is in accordance with several reports, described in further 
detail in the discussion, stating that MTX does not have a direct effect on IL-6 levels in primary 
RASF cells. At 48 hours, (Fig. 17B) although trends similar to 24 hours are seen with reductions 
in IL-6 levels in response to NP-ODN, NP-MTX and NP-ODN-MTX, significant reductions 
were not observed in response to any NP treatment.  
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The IL-8 secretion response of primary RA cells to NP treatments is depicted in Fig. 18. At 
24 hours (Fig. 18A), despite similar reduction trends as observed for primary IL-6 secretion and 
SW982 IL-8 secretion, the differences were not significant. At 48 hours, (Fig. 18B) NP-ODN, 
NP-MTX, NP-ODN-MTX, and MTX alone all resulted in significant decreases in IL-8 secretion 
when compared to the untreated control. Furthermore, NP-ODN-MTX treatment resulted in a 
significant decrease when compared to ODN alone. 
5.3.2 Cellular uptake of NP-ODN 
Fig. 18. ELISA was performed to determine levels of IL-8 secretion by primary RA synovial 
fibroblast cells, after treatment with ODN alone (ODN), NP coated with ODN (NP-ODN), NP 
loaded with methotrexate (NP-MTX), NP loaded with methotrexate and ODN (NP-ODN-
MTX), and MTX alone (MTX) and stimulation with IL-1B at 24 (A) and 48 (B) hours. Results 
are expressed as fold changes of IL-8 levels relative to an untreated control, shown as a solid 
line at 1. One way ANOVA followed by Holm-Sidak multiple comparisons testing was used 
to determine the impact of treatment on IL-8 secretion. * represents a significant difference 
from the control, while † represents significant difference from ODN alone. All data is 
presented as mean ± SD (N=4). 
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To facilitate visualization of carrier uptake and localization of NP in vitro, TMC was 
modified with green (Alexa Fluor 488) fluorescent tag. Tagged NP were incubated with SW982 
cells at 37°C for 45 minutes, and visualized. A composite image from the uptake experiments is 
shown in Fig. 19. The nanoparticles demonstrated sufficient cellular uptake within a short time 
period. 
5.4 Discussion 
A major barrier in the advancement of nucleic acid therapies to achieving clinical relevance 
is a general lack of ability of the negatively charged nucleic acid to enter the negatively charged 
cell membrane. A number of positively charged carrier systems and transfection reagents have 
Fig. 19. Cellular uptake visualization of Alexa Fluor 488® tagged PSA-TMC in 
SW982 synovial sarcoma cells. Cells were incubated with tagged particles for 45 
minutes at 37°C, then imaged using an inverted fluorescent microscope.  
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been explored to overcome this barrier; however, many of these are associated with toxicity, 
immunogenicity, and/or are highly variable based on cell type [182]. The carrier system 
presented here, PSA-TMC nanoparticles, has been found to be non-cytotoxic, while maintaining 
a positive surface charge [145, 156, 174]. The positive surface charge of the particles due to 
TMC is expected to facilitate interaction with negatively charged cell membranes, increasing 
ODN cellular uptake. Meanwhile, PSA has no known receptors in the body, making it an optimal 
choice for a component, as this will likely allow for RES evasion and reduce the likelihood of 
inducing an immune response. Further, PSA has properties similar to polyethylene glycol (PEG), 
a polymer commonly used to extend circulation time via incorporation into nanocarrier systems 
or protein conjugates [7, 145, 149, 158]. In sum, a nanoparticle system based on natural 
polysaccharides, anticipated to exhibit reduced immunogenicity and enhanced hydrophilicity in 
comparison to other cationic polymer based nanocarrier systems is reported in this chapter. An 
NF-kB decoy ODN was chosen as the NA drug of choice for this study due to the known activity 
of NF-kB in RA pathology.  
Under normal conditions, NF-κB is bound to an inhibitor in the cytoplasm. However, in 
response to an inflammatory stimulus, the inhibitor undergoes phosphorylation, leading to 
dissociation of the NF-κB/inhibitor complex and subsequent nuclear translocation of the 
transcription factor. For this study, IL-6 and IL-8 were chosen as the representative cytokine and 
chemokine, respectively for quantitative analysis. In addition to other roles in the inflammatory 
response, IL-6 and IL-8 play a role in stimulation of VEGF, a growth factor linked to production 
of blood vessels [125]. The newly and, hence, typically rapidly formed blood vessels have larger 
pore sizes between the endothelial barrier than normal blood vessels, which can be exploited for 
drug delivery via the enhanced permeation and retention (EPR) effect [183]. Colloidal carrier 
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systems between 100-200 nm can passively accumulate in areas associated with blood vessels 
with larger, leaky pores in the endothelial barrier, thus, the EPR effect is a means of passive 
targeting [184]. While RA pathology doesn’t exhibit the retention aspect of this phenomenon, the 
enhanced permeation appears to be great enough to act as a passive targeting mechanism [185, 
186]. 
As NF-κB has a well-established involvement in RA, the transcription factor is an enticing 
target for drug candidates. However, as demonstrated here and in previous studies, 
administration of decoy ODN’s alone results in low efficacy and delivery with many available 
reagents results in high degrees of cytotoxicity  [174]. In the current study, decoy ODN efficacy 
was increased when administered via PSA-TMC to primary and cell line in vitro models of RA. 
SW982 cells yielded significantly decreased levels of IL-6 in response to treatment with 
NPODNMTX at 24 and 48 hours and in response to NPMTX at 48 hours only. As primary cells 
are isolated from different individuals, it is not unexpected to observe increased variability 
among cytokine expression and secretion when compared to cell line groups, as seen here [187].  
In regards to the effect of MTX on cytokine modulation, conflicting results have been 
reported. Early research by Loetscher et al. claimed that MTX is ineffective at mediating IL-8 
production in RA [188], while Kraan et al. reported decreased IL-8 in synovial fluid after MTX 
treatment [189]. Similarly, Nishina et al. recently reported MTX effectively reduced IL-6 plasma 
levels in RA patients [190], while Inoue et al. claimed MTX did not have an inhibitory effect on 
IL-6 production by RA synovial cells [191]. Previous studies conducted by our group found 
MTX delivery alone to be inconsistent, providing further evidence that the therapeutic effects of 
MTX may not be manifested in changes in the cytokine milieu [145].  
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The cytokine results portrayed in Figs. 15 through 18 in response to MTX alone are reflective 
of the variable response observed among RA patients. In addition to unpredictable efficacy, 
MTX is associated with a number of severe, dose dependent side effects, limiting the tolerable 
dosage level. Several reports advocate for combination therapy of DMARDs, particularly MTX, 
with biologic therapies. For example, a report by Goekoop-Ruiterman et al claimed increased 
clinical improvement in early stages of diseases progression with combination therapies [192]. 
Likewise, claims of increased efficacy of low dose of MTX combined with alternative therapies, 
such as phosphodiesterase type three inhibitor cilostazol have also been reported [193]. Indeed, 
primary RASF cells showed a significant response in IL-6 levels to treatment with NP-ODN-
MTX and NP-ODN, but not NP-MTX or MTX alone. The primary cell model also resulted in a 
significant reduction of IL-8 in response to NP-ODN, NP-MTX, NP-ODN-MTX and MTX in 
comparison to an untreated control, however only NP-ODN-MTX resulted  in a significant 
decrease in comparison to just ODN delivery alone. These results suggest that decoy ODN has 
the ability to act alone, as well as enhance efficacy of DMARD MTX when delivered in 
combination. PSA-TMC NP provide a delivery vehicle to safely enhance cellular uptake of 
ODN, as well as encapsulate and carry MTX to the required site of action.  
5.5 Conclusion 
In this study, evidence furthering the claim that PSA-TMC nanoparticles can be used to 
effectively deliver nucleic acid based drugs was obtained. Furthermore, the combination of NF-
κB decoy ODN and DMARD MTX was shown to result in an increased reduction in 
inflammatory cytokines in both a cell line and primary RASF model of RA. To our knowledge, 
this is the first report of investigating combination therapy of MTX with a decoy ODN. While 
PSA-TMC nanoparticles have been used to administer both MTX and ODN separately in 
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previous studies, this is the first time we have attempted to combine these two therapies and 
report successful modulation of inflammatory proteins in RA in vitro models [145, 174]. 
Incorporating in vivo testing is necessary to determine both safety and efficacy of PSA-TMC 
loaded with ODN and MTX, however this preliminary in vitro investigation provides strong 
evidence to support future studies. 
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6. Immunomodulation of Cystic Fibrosis Epithelial Cells 
via NF-κB Decoy Oligonucleotide Coated Polysaccharide 
Nanoparticles 
Activation of the transcription factor nuclear factor-kappa B (NF-κB) signaling pathway 
is associated with enhanced secretion of proinflammatory mediators and is thought to play a 
critical role in diseases hallmarked by inflammation, including cystic fibrosis (CF). Small nucleic 
acids that interfere with gene expression have been proposed as promising therapeutics for a 
number of diseases. However, applications have been limited by low cellular penetration and a 
lack of stability. Nano-sized carrier systems have been suggested as a means of improving the 
effectiveness of nucleic-acid based treatments. Polysialic acid-N-trimethyl chitosan (PSA-TMC) 
nanoparticles were successfully coated with NF-κB decoy oligonucleotides (ODNs). To 
demonstrate anti-inflammatory activity, this chapter describes use of a simple in vitro model of 
CF generated via interleukin-1β or P. aeruginosa lipopolysaccharides stimulation of IB3-1 
bronchial epithelial cells. While free ODN and PSA-TMC nanoparticles coated with scrambled 
oligonucleotides did not have substantial impacts on the inflammatory response, the decoy ODN-
coated PSA-TMC nanoparticles were able to reduce the secretion of interleukin-6 and 
interleukin-8, proinflammatory mediators of CF, by the epithelial cells, particularly at longer 
time points. In general, the results suggest that NF-κB decoy ODN-coated TMC-PSA 
nanoparticles may serve as an effective method of altering the proinflammatory environment 
associated with CF. 
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6.1 Introduction 
Cystic fibrosis (CF) is an autosomal recessive genetic disorder characterized by mutations in 
the gene encoding the cystic fibrosis transmembrane conductance regulator protein (CFTR) that 
controls chloride ion transport in epithelial surfaces [194]. Disruption of ion transport leads to 
excessive mucus buildup, affecting many organs; however, chronic lung disease due to persistent 
infection and inflammation presents the highest morbidity risk [195, 196]. Although the 
mechanisms behind the onset and perpetuation of inflammation are not fully understood, many 
reports agree that elevated levels of transcription factor nuclear factor-kappa light chain enhancer 
of activated B cells (NF-κB) within the lung epithelia are associated with the inflammatory 
immune response. NF-κB is known to transcriptionally regulate the production of a variety of 
inflammatory mediators, including interleukin-8 (IL-8) and interleukin-6 (IL-6), cytokines 
directly involved in the immune response [197]. IL-6 stimulates B cells, leading to increased 
antibody production, while IL-8 recruits neutrophils to the infected area [198-200]. In contrast to 
CF bronchial epithelial cells that show significantly elevated levels of IL-6 and IL-8, healthy 
cells yield levels of these cytokines that are not readily detectable [200]. 
Pseudomonas aeruginosa, a pathogen commonly found in CF lung infections, is known to 
activate the NF-κB signaling pathway via interactions with the toll-like receptors (TLR). 
Notably, P. aeruginosa lipopolysaccharides (pLPS) interact with the NF-κB pathway through 
TLR-4 [201]. As illustrated in Fig. 20, under normal circumstances, NF-κB is sequestered in the 
cytoplasm by a protein known as inhibitor of κB (IκB). In the event of inflammatory stimuli 
receptor binding, such as binding of pLPS to TLR 4, IκB kinase (IκK) is activated, which 
phosphorylates and inactivates IκB. Dissociation of NF-κB then occurs, followed by 
translocation to the nucleus and initiation of transcription [119]. Blocking NF-κB nuclear 
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translocation and/or DNA binding with a transcription factor decoy oligonucleotide (ODN) 
therefore has the potential to reduce inflammation in CF airways (Fig. 20) [202].  
NF-κB transcription factor decoy ODNs have previously been explored as anti-inflammatory 
treatments for several conditions, including CF. A review by De Stefano highlights some of the 
recent applications of NF-κB transcription factor decoy ODN’s in the treatment of inflammatory 
diseases [203], and several groups have reported suppression of inflammatory cytokines in 
response to an NF-κB decoy ODN in in vitro and in vivo disease models [4, 204-207]. For 
example, NF-κB decoy ODNs complexed with cationic liposomes were shown to reduce the 
expression of IL-8 by IB3-1 bronchial epithelial cells infected with P. aeruginosa[4]. However, 
Fig. 20 An illustration of NF-κB pathway activation in a CF airway epithelial cell. P. 
aeruginosa bacterial components bind to the toll-like receptors, leading to activation of IκK, 
phosphorylation and inactivation of IκB, and eventual translocation of NF-κB to the 
nucleus.NF-κB decoy ODNs prevent translocation and transcription of NF-κB dependent 
genes. 
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use of decoy ODNs as therapeutic agents, particularly for diseases that necessitate systemic 
administration, has hampered by two major drawbacks: (1) the negative charge prevents cellular 
uptake and (2) the short nucleic acid molecules are unstable and susceptible to nuclease activity 
[119]. Reflecting this potential limitation in activity, one clinical trial has been conducted with 
local administration of NF-κB decoy oligonucleotides using a non-viral vector, but the study was 
closed due to a lack of demonstrated efficacy, presumably as a result of rapid enzymatic 
digestion [101]. As detailed in previous chapters, viral vectors and cationic lipid reagents, the 
current options for nucleic acid delivery are often associated with immunogenicity and 
cytotoxicity, rendering them inappropriate for use in applications where control of inflammation 
is the desired outcome [100, 101] [105]. 
 Here, the PSA-TMC nanoparticles, described in detail in chapter four, were coated with 
NF-κB decoy ODN, and the ability of the ODN-coated nanoparticles to reduce the inflammatory 
response associated with CF was demonstrated using an in vitro model based upon the IB3-1 cell 
line. Although several immortalized cell lines derived from bronchial epithelial cells exist for 
therapeutic screening, the IB3-1 CF cell line, which express the mutated CFTR protein, was used 
for the research presented herein based upon prior use of these cells for gene therapy [4], in 
conjunction with evidence of a strong pro-inflammatory response to stimuli derived from P. 
aeruginosa [4, 208, 209]. Prior to conducting anti-inflammatory efficacy studies, toxicity of the 
nanoparticles toward the IB3-1 cell line was assessed. Anti-inflammatory activity was assessed 
by determining changes in the secretion of IL-6 and IL-8 upon stimulation with either 
interleukin-1β (IL-1β) or pLPS after pre-treatment of the cells with of the decoy ODN-coated 
nanoparticles. Similar to other investigators, the direct impact of the decoy ODNs on the NF-κB 
signaling pathway was evaluated with a luciferase reporter assay using HEK 293 cells.  
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6.2 Materials and methods  
6.2.1 Materials  
Polysialic acid (colominic acid, PSA) was obtained from Nacalai USA, Inc. (San Diego, 
CA, USA). N-trimethyl chitosan (TMC) was produced via quaternization of chitosan (MW 100 
Da – 300 kDa) obtained from Acros Organics (New Jersey, USA), as described by Sieval et al 
[163]. Sodium tripolyphosphate (pure, TPP) was procured from Acros Organics (New Jersey, 
USA). P.aeruginosa LPS (pLPS) was purchased from Sigma Aldrich (St. Louis, MO, USA). An 
NF-κB decoy oligonucleotide (ODN) kit containing NF-κB decoy ODN (5’ CCT TGA AGG 
GAT TCC CCT CC 3’), as well as scrambled ODN (5’ TTG CCG TAC CTG ACT TAG CC 3’), 
was acquired from CosmoBio (Tokyo, Japan). Recombinant human interleukin-1β was obtained 
from R and D systems (Minneapolis, MN).  A rhodamine tagged ODN (5’ (TAMRA-X) (C6-
NH) CCT TGA AGG GAT TTC CCT CC 3’) was purchased from TriLink Biotechnologies (San 
Diego, CA). Lipofectamine 2000 transfection reagent and 4', 6-Diamidino-2-Phenylindole, 
dilactate (DAPI stain) were procured from Invitrogen (Grand Island, NY).  
6.2.2 Cell culture 
IB3-1 bronchial epithelial cells with the CF CFTR gene mutations were obtained from 
the Johns Hopkins GCFR cell center and grown on rat tail collagen coated tissue culture flasks. 
To coat the flasks, rat tail collagen was dissolved in LHC-8 complete growth media (Invitrogen, 
Grand Island, NY) at a concentration of 30 ng/ml. LHC media has been optimized for the growth 
of bronchial epithelial cells. 1.5 ml of the coating solution was added to a 25 cm2 tissue culture 
flask and incubated at 37oC, 5% CO2 for 24-48 hours. Coating media was removed prior to 
placing cells in the flask, and cells were maintained in LHC-8 with 5% fetal bovine serum (FBS, 
Atlanta Biologicals, Atlanta GA) at 37oC, 5% CO2 until confluent. Human embryonic kidney 
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(HEK) 293 cells were obtained from ATCC (Manassas, VA) and cultured in Dulbecco’s 
Modified Eagles Medium (DMEM) with 10% FBS at 37°C, 5% CO2. 
6.2.3 Nanoparticle preparation and characterization 
  PSA-TMC nanoparticles (NP) were prepared as previously described, and detailed in 
chapter four [156]. A Malvern Zetasizer NanoZS90 (Malvern Instruments, Malvern UK) was 
used to determine nanoparticle size, polydispersity (PDI), and zeta potential.  
6.2.4 Cytotoxicity of PSA-TMC towards IB3-1 cells 
PSA-TMC cytotoxicity was assessed using a CCK-8 cell counting kit (Dojindo Molecular 
Technologies, Rockville Md.). IB3-1 cells were plated on a 96 well tissue culture plate (5000 
cells/well) and allowed 24 hours for complete adherence. PSA-TMC was prepared as described 
above, resuspended in LHC-8 + 5% FBS media after centrifugation, sterile filtered, and added at 
concentrations ranging from 10 mg/ml to 0 mg/ml to IB3-1 cells in duplicate. After incubation at 
37°C for 24 hours, changes in cellular metabolic activity were determined following the 
manufacturer’s instructions. Briefly, 10 µl of reagent and 100 µl of media were added to each 
well; and, after incubating at 37°C for 90 minutes, colorimetric absorbance at 450 nm was 
quantified using a BioTek Synergy 2 multimode plate reader (BioTek Instruments, Winooski, 
VT).  
6.2.5 In vitro efficacy of ODN-coated PSA-TMC nanoparticles 
IB3-1 cells were plated on collagen coated 24 well plates at a density of 20,000 cells per 
well. LHC-8 media supplemented with 5% FBS was added to bring the volume per well to 500 
µl, and 24 hours were allowed for cellular adherence. Decoy and scrambled ODN-coated PSA-
TMC nanoparticles (NP-ODN and NP-SCO, respectively), as well as bare PSA-TMC 
nanoparticles (NP), were prepared as described in chapter four. Immediately following 
85 
 
centrifugation, NP-ODN, NP-SCO, and NP were resuspended in LHC-8 (without FBS) at a 
concentration of 1 mg/ml and filtered through a sterile 0.45 micron filter. As a positive control, 
Lipofectamine 2000-Decoy ODN complexes (Lipo-ODN) were prepared as directed by the 
manufacturer. In two separate microcentrifuge tubes, 2.5 µl of Lipofectamine 2000 reagent and 
500 ng decoy ODN were added to 50 µl of serum free media. After equilibrating for 5 minutes, 
the reagent media was added to the ODN media, and the resultant solution was incubated for 15 
minutes to allow for complex formation. 500 µl of the following treatment groups were added to 
the prepared 24 well plate in duplicate: 1. media alone, 2. ODN alone, 3. NP-ODN, 4. NP, 5. 
Lipo-ODN, and 6. NP-SCO. After 4 hours, the treated media was removed and replaced with 
fresh media containing 5% FBS to allow for normal growth conditions.  
24 hours after media replacement, cells were stimulated with IL-1β (2.5 ng/ml) or pLPS (10 
µg/ml) to induce inflammation. The concentration of IL-1β used correlates to the concentration 
that yielded a 50% increase in the secretion of prostaglandin E2 (PGE2) upon administration to 
IB3-1 cells. Similarly, LPS has been reported to increase levels of IL-6 and IL-8 when 
introduced at a concentration of 10 µg/ml [202]. After incubation at 37°C for 24 or 48 hours, the 
supernatant was collected and stored at -80°C degrees until analysis. DAPI nuclear staining was 
conducted immediately after sample collection to determine cell count for normalization. Briefly, 
DAPI dye (5 mg/ml stock concentration) was diluted to 0.5 µg/ml with 1X PBS and 250 µl were 
added to each well. After 1 minute, the dye was removed and the cells were rinsed 3 times with 
PBS. Imaging was performed using an inverted fluorescence microscope (Leica Microsystems, 
IL, USA). Three representative images were obtained from each well. Each image was counted, 
and a mean cell number (MCN) was generated for each condition. Total cell number (TCN) was 
determined using the following equation: 
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                                              𝑇𝐶𝑁 = 𝑀𝐶𝑁 ∗ (
𝐴𝑤𝑒𝑙𝑙
𝐴𝑖𝑚𝑎𝑔𝑒
)                                                  (5) 
where Awell is the total area of the well, and Aimage  is the area of the image obtained by 
microscopy. 
6.2.6 Quantitative analysis of inflammatory cytokines  
IL-6 and IL-8 ELISA kits were purchased from Peprotech (Rocky Hill, NJ) and run 
according to manufacturer’s instructions to determine the levels of IL-6 and IL-8 in the collected 
supernatant. Samples were run in duplicate, and each experiment was repeated independently 
three times.  
6.2.7 Cellular response to TMC and PSA 
Based upon a recent literature report, TMC can have an anti-inflammatory impact on cells 
stimulated by LPS [210]. Therefore, 500 µl of TMC and PSA in LHC-media (without FBS) at 
concentrations of 1 mg/ml were added to IB3-1 cells cultured in a 24 well plate in duplicate. 
After 4 hours, the treated media was removed and replaced with fresh media containing 5% FBS 
to allow for normal growth conditions. 24 hours after media replacement, cells were stimulated 
with pLPS (10 µg/ml) to induce inflammation. After incubation at 37°C for 24 or 48 hours, the 
supernatant was collected and stored at -80°C degrees until analysis. DAPI nuclear staining was 
conducted immediately after sample collection to determine cell count for normalization, as 
described in Section 2.6. IL-6 ELISA (Section 2.7) was used to quantify the amount of IL-6 
within the collected supernatant. The experiment was repeated independently three times.   
6.2.8 Luciferase reporter assay 
HEK 293 cells were transfected with a pMetLuc Reporter Vector, part of a Ready-To-Glow 
Secreted Luciferase Reporter System acquired from Clontech (Mountain View, CA). For each 
transfection, 0.5 µg of the NF-κB dependent pMetLuc reporter, which leads to the production 
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and secretion of luciferase protein in response to NF-ƘB activation, or 0.5 µg of a control vector 
were prepared in Lipofectamine LTX reagent (Invitrogen, Grand Island, NY) according to the 
manufacturer’s instructions. After incubation with the reporter complexes for 4 hours, cells were 
treated with ODN-coated nanoparticles and controls, as described in Section 2.6 (media alone, 
ODN alone, NP-ODN, NP, Lipo-ODN and NP-SCO). Following incubation for an additional 4 
hours, the treatment media was replaced with DMEM supplemented with 10% FBS. 24 hours 
after media replacement, cells were stimulated with IL-1β (2.5 ng/ml) to induce inflammation. 
Supernatant samples were collected at 24 hours and assayed for luciferase activity using the 
luminescence assay included in the Clontech kit. Luciferase activity was normalized to the 
control vector, and each experiment was repeated independently 3 times. 
6.2.9  Cellular immunostaining 
Immunofluorescent staining of the NF-B subunit was used to qualitatively verify that the 
ODN-coated nanoparticles blocked nuclear translocation of NF-B following stimulation of IB3-
1 cells. The staining protocol was optimized based upon prior work by Nadjar et al [211].   100,000 
cells were plated onto collagen-coated confocal dishes (MatTeck Corporation, Ashland, MA) and 
allowed to adhere overnight. ODN-coated PSA-TMC nanoparticles were prepared as described 
above and added to a confocal dish at a concentration of 1 mg/ml. As controls, confocal dishes 
were prepared that contained either media or ODN (500 ng/ml) alone. After 4 hours, ODN and 
ODN-coated PSA-TMC nanoparticles were removed and replaced with LHC-8 media with 5% 
FBS. 24 hours later, the cells were stimulated with IL-1β at a concentration of 2.5 ng/ml to induce 
inflammation. After 48 hours, the cells were fixed in a 4% paraformaldehyde solution for 15 
minutes.  Subsequently, the cells were permeabilized with a 1.0% Tritonx-100 for 10 minutes after 
rinsing 2-3 times with 1X PBS.  After again rinsing with 1X PBS 2-3 times, a 3% BSA blocking 
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solution was added to the cells for 30 minutes to prevent nonspecific binding. Following an 
additional 2-3 rinses with 1X PBS, NF-kB (P65) NLS polyclonal antibody (primary) was added at 
a concentration of 2 µg/ml, and the cells were incubated overnight at 4oC.  The primary antibody 
was removed, and the cells were rinsed 4 times in 1x PBS.  FITC-Goat anti-rabbit IgG (secondary) 
was added at a concentration of 2 µg/ml and incubated for 2 hours at room temperature.  Secondary 
antibody was removed, and the cells were rinsed 4 times in 1x PBS. TO-PRO-3 nuclear stain 
(Invitrogen, Grand Island, NY) was added at a concentration of 5 μl/ml and incubated for 45 
minutes. Cells were rinsed and imaged with a Nikon Eclipse Ti inverted microscope. 
6.2.10  Statistical analysis 
Protein levels were normalized to cell number and expressed relative to the untreated, 
stimulated control group. Luciferase activity was normalized to the control vector. Data is 
presented as mean ± standard deviation for all groups (N=3). To compare protein secretion and 
luciferase activity following different treatments and IL-1β or LPS stimulation, one-way 
ANOVA, followed by a Holm-Sidak test for multiple comparisons [212, 213], was performed. 
The Student’s t-test was used to compare the sizes, zeta potentials, and PDI of ODN-coated 
nanoparticles to those of bare nanoparticles. The latter test was also used to compare IL-6 
secretion of cells treated with PSA or TMC and stimulated with LPS to untreated, LPS-
stimulated cells. All statistical tests were conducted with a significance level (alpha) of 0.05.  
6.3 Results  
6.3.1 In vitro anti-inflammatory efficacy 
Prior to testing of in vitro efficacy, the cytotoxicity of the PSA-TMC nanoparticles towards IB3-
1 cells was established (Fig. 21). As anticipated based upon prior testing with the  MH7A and 
SW-982 cell lines [145, 156], no changes in cellular proliferation were observed for IB3-1 cells 
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with addition of PSA-TMC concentrations up to 10 mg/ml [156]. Therefore, bare nanoparticles 
administered at a concentration of 1 mg/ml for in vitro testing (1 mg/ml) were expected to yield a 
minimal change in cellular inflammatory response.  
Fig 21: In vitro cytotoxicity of PSA-TMC toward IB3-1 cells. The particles were observed to 
be non-toxic up to the highest tested concentration, 10 mg.  
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IL-6 and IL-8 secretion levels were first examined in response to stimulation with IL-1β, a 
pro-inflammatory mediator secreted by mammalian cells. As shown in Fig. 22B, the ODN-
coated nanoparticles evoked a significant decrease in IL-8 secretion at 48 hours relative to 
stimulated control cells. Although not significant, a similar decrease was observed at 24 hours 
(Fig. 22A). As expected, ODN alone, bare nanoparticles, and nanoparticles coated with SCO did 
not result in any changes in IL-8 levels. At first glance, ODN delivered using Lipofectamine 
2000, a commercially available and commonly used transfection reagent, also appears to 
effectively lower IL-8 expression at 24 and 48 hours. However, Lipofectamine 2000 was highly 
cytotoxic to the IB3-1 cells, resulting in significant cell death and consequently lower levels of 
cytokine production due to low cell number. Additionally, cell counting for normalization was 
Fig. 22. ELISA was performed to determine levels of IL-8 secretion after treatment with bare 
nanoparticles (NP), ODN alone (ODN), NF-κB decoy ODN-coated nanoparticles (NP-ODN), 
scrambled ODN-coated nanoparticles (NP-SCO), or ODN complexed with Lipofectamine 
2000 (Lipo-ODN) and stimulation with IL-1β at 24 (A) and 48 (B) hours.  Results are 
normalized to cell number and expressed as fold changes of IL-8 levels relative to a non-
treated control, indicated by a solid line at 1. All data is presented as mean + SD (N=3).  One 
way ANOVA followed by a Holm-Sidak test for multiple comparisons was used to assess the 
impact of treatment on protein secretion. * indicates a significant difference (p < 0.05) 
between the treatment and the non-treated control. 
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difficult for this condition due to a general lack of cells.  Live-dead staining was used to further 
demonstrate the cell death that resulted from exposure to Lipofectamine 2000, and shown in Fig. 
23.  
Fig. 23. Live-dead staining was used to verify that Lipofectamine induced cell 
death in IB3-1 cells. As expected, ODN did not result in a change in cellular 
viability. (Scale bar = 200 µm) 
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IL-6 is a potent cytokine involved in general up-regulation of inflammation, whose 
production, like that of IL-8, is known to be enhanced through an IL-1β mediated increase in NF-
κB signaling [214]. Fig. 24 illustrates the response of IB3-1 cells to stimulation with IL-1β 
following ODN delivery treatments. Consistent with the observations for IL-8, the ODN-coated 
nanoparticles appeared to lower IL-6 vales compared to the untreated control at 24 (Fig. 24A) 
and 48 hours (Fig. 24B), with a slightly lower mean value at 48 hours than at 24. Likewise, ODN 
alone, bare nanoparticles, and SCO-coated nanoparticles did not result in a change in IL-6 
secretion.  
Fig. 24. ELISA was performed to determine levels of IL-6 secretion after treatment with 
bare nanoparticles (NP), ODN alone (ODN), NF- -coated nanoparticles 
(NP-ODN), scrambled ODN-coated nanoparticles (NP-SCO), or ODN complexed with 
Lipofectamine 2000 (Lipo-ODN) and stimulation with IL-1β for 24 (A) and 48 (B) hours.  
Results are normalized to cell number and expressed as fold changes of IL-6 levels relative 
to a non-treated control, indicated by a solid line at 1. All data is presented as mean ± SD 
(N=3).  One way ANOVA followed by a Holm-Sidak test for multiple comparisons was 
used to assess the impact of treatment on protein secretion. 
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IL-6 and IL-8 secretion were also investigated in response to stimulation with LPS isolated from 
P. aeruginosa, i.e. a pro-inflammatory mediator released by bacteria cells. LPS is a known 
activator of the NF-κB pathway via the toll-like receptor-4 (TLR-4) [215]. IL-8 secretion in 
response to LPS stimulation is shown in Fig 25. Similar to IL-8 levels in response to IL-1β, 
ODN-coated nanoparticles resulted in significantly lower levels of IL-8 at 48 hours (Fig. 25B). 
At 24 hours, a decrease in IL-8 when treated with ODN-coated nanoparticles was shown, 
although the difference was not significant (Fig. 25A). Furthermore, ODN alone, bare 
nanoparticles, and nanoparticles coated with SCO did not result in any significant changes in IL-
8 levels at either time point.  
Fig. 25. ELISA was performed to determine the level of IL-8 secretion after treatment 
with bare nanoparticles (NP), ODN alone (ODN), NF-κB decoy ODN-coated 
nanoparticles (NP-ODN), scrambled ODN-coated nanoparticles (NP-SCO), or ODN 
complexed with Lipofectamine 2000 (Lipo-ODN) and stimulation with pLPS for 24 (A) 
and 48 (B) hours.  Results are normalized to cell number and expressed as fold changes 
relative to a non-treated control, indicated by a solid line at 1. All data is presented as 
mean ± SD (N=3). One way ANOVA followed by a Holm-Sidak test for multiple 
comparisons was used to assess the impact of treatment on protein secretion. * indicates a 
significant difference (p < 0.05) between the treatment and the non-treated control.   
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For LPS induced IL-6 secretion, at 24 hours (Fig. 26A), ODN-coated nanoparticles resulted 
in a non-significant decrease in IL-6, similar to what was observed for stimulation via IL-1β. 
However, bare nanoparticles and nanoparticles coated with SCO also resulted in IL-6 decreases, 
Fig. 26 ELISA was performed to determine the level of IL-6 secretion after treatment with bare 
nanoparticles (NP), ODN alone (ODN), NF-κB decoy ODN-coated nanoparticles (NP-ODN), 
scrambled ODN-coated nanoparticles (NP-SCO), or ODN complexed with Lipofectamine 2000 
(Lipo-ODN) and stimulation with pLPS for 24 (A) and 48 (B) hours.  Results are normalized to 
cell number and expressed as fold changes relative to a non-treated control, indicated by a solid 
line at 1. All data is presented as mean ± SD (N=3). One way ANOVA followed by a Holm-
Sidak test for multiple comparisons was used to assess the impact of treatment on protein 
secretion. * indicates a significant difference (p < 0.05) between the treatment and the non-
treated control.   
Fig. 27. ELISA was performed to 
determine the level of IL-6 
secretion following treatment with 
the nanoparticle components, PSA 
and TMC, and stimulation with 
pLPS for 24 and 48 hours. Results 
are normalized to cell number and 
expressed as fold changes relative 
to a non-treated control, indicated 
by the solid line at 1.  
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although the change was not significant. Free ODN alone again did not yield a change in IL-6 
secretion. Similarly, at 48 hours (Fig. 26B), ODN-coated nanoparticles, as well as bare 
nanoparticles, resulted in significantly lower levels of IL-6 secretion than the untreated control. 
SCO coated nanoparticles resulted in slightly lower IL-6 levels as well, while ODN alone did not 
effect a change. To further investigate the significant reduction in IL-6 secretion observed at 48 
hours for the bare nanoparticles, LPS induced secretion of IL-6 was also assessed following 
treatment with TMC and PSA alone. As shown in Fig. 27, PSA alone did not result in a 
significant change in 
IL-6 secretion at 24 
or 48 hours; 
however, TMC alone 
resulted in 
significantly lower 
IL-6 levels at 48 
hours.    
    
6.3.2 Luciferase 
reporter assay 
The impact of the 
ODN-coated 
nanoparticles on NF-
κB dependent gene 
expression was 
Fig. 28: A luciferase reporter assay was used to examine the effect of 
the decoy ODN-coated nanoparticles on NF-κB dependent gene 
expression. HEK 293 cells were transfected with luciferase reporter 
plasmid, treated with the NF-κB decoy ODN-coated nanoparticles or 
controls, and stimulated with IL-1β (2.5 ng/ml). All data is presented 
as mean ± SD (N=3). One way ANOVA followed by a Holm-Sidak 
test for multiple comparisons was used to assess the impact of 
treatment on luciferase activity. * indicates a significant difference (p 
< 0.05) between the treatment and the non-treated control.   
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further examined using a luciferase reporter assay, whereby induction of NF-κB dependent genes 
results in the secretion of a reporter molecule into the supernatant. The HEK 293 cell line was 
used in lieu of the IB3-1 cell line based upon ease of transfection. As shown in Fig. 28, NF-κB 
decoy ODN-coated nanoparticles resulted in a significant reduction in the expression of NF-κB 
dependent genes, as indicated by a decrease in luciferase activity. In contrast, ODN alone, bare 
nanoparticles, and nanoparticles coated with SCO did not result in significant changes in the 
expression of NF-κB dependent genes. Luciferase activity for cells treated with Lipo-ODN could 
not be determined due to a lack of viable cells.  
6.3.3  Cellular immuno-staining 
Fluorescence microscopy was used to add credence to the notion that NF-B decoy 
ODN-coated nanoparticles trap NF-kB within the cytoplasm, 
thereby reducing nuclear translocation and subsequent proinflammatory signaling. IL-1 
stimulated cells were fixed and labelled with anti-NF-B p65 antibody following treatment with 
Fig. 29: Intracellular 
distribution of the NF-κB 
p65 subunit after 
treatment of IL-1β 
stimulated cells with 
ODN and NP-ODN. 
Cells were fixed and 
labelled with anti-NF-kB 
p65 antibody and nuclei 
were counterstained with 
TO-PRO-3. Treatment 
with ODN alone did not 
alter distribution of NF-
κB relative to the control, 
while NP-ODN 
sequestered much of the 
NF-κB in the cytoplasm. 
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ODN alone or ODN-based nanoparticles (Fig. 29).  Counterstaining with TO-PRO-3 nuclear dye 
allowed for enhanced distinction between cytoplasmic and nuclear NF-kB. As anticipated, ODN-
coated nanoparticles trapped NF-kB within the cytoplasm relative to untreated, stimulated cells, 
while administration of ODN alone did not lead to a distinguishable difference from the control.  
6.4 Discussion 
A limiting factor in the advancement of oligonucleotide applications in cellular 
environments is a general inability of the negatively charged nucleic acids to interact with and 
penetrate the negatively charged lipid bilayer membranes. As a way of circumventing this 
problem, a number of positively charged transfection reagents are commercially available. 
Although these reagents have been somewhat successful, many cationic transfection reagents are 
notorious for being cytotoxic, and their efficacy is highly variable based on cell type. For 
example, Lipofectamine 2000 yields an overall decrease in cellular protein content at the dose 
required for optimal transfection efficiency, indicating high cytotoxicity [216]. Additionally, 
strong uptake of Lipofectamine-based lipoplexes by the RES occurs in vivo [217]. As discussed 
within the Introduction, the positive zeta potential of the PSA-TMC nanoparticles imparted by 
the quaternized chitosan is expected to facilitate nucleic acid binding, as well as membrane 
adhesion and penetration, thereby achieving delivery of associated ODNs into the cell. The 
presence of PSA in the nanoparticles is presumed to reduce protein interactions and limit 
interactions with the RES [135-137]. Thus, PSA offers a natural, biodegradable, non-
immunogenic alternative to PEG for extending circulatory stability.  
Bioactivity of the NF-κB decoy ODN-coated PSA-TMC nanoparticles was established by 
assessing changes in the secretion of two proinflammatory mediators, IL-6 and IL-8, associated 
with the NF-κB pathway by activated IB3-1 cells. Under normal conditions, NF-κB transcription 
98 
 
factor is located in the cytoplasm, bound to IκB inhibitor. However, stimulation with various 
pro-inflammatory factors, including IL-1β and LPS, as used in the current study, leads to 
activation of a kinase responsible for phosphorylating IκB, causing dissociation and inactivation 
[218, 219]. Without sequestration by IκB in the cytoplasm, NF-κB is free to translocate to the 
nucleus, and transcription of various proteins, including IL-6 and IL-8, is initiated. A 
transcription factor decoy ODN introduced to the cytoplasm will intercept NF-κB, thereby 
preventing translocation to the nucleus and mitigating expression of genes linked to additional 
proinflammatory mediators (Fig. 21). 
  Using IB3-1 cells, IL-1β activation of NF-κB has been shown to be a major contributing 
factor to elevated IL-8 levels in the CF lung epithelium [220]. Nanoparticles coated with ODN 
effectively lowered IL-8 secretion levels in response to stimulation with IL-1β in this study. Of 
note, the PSA-TMC nanoparticles did not exhibit cellular toxicity, as indicated by a cellular 
proliferation assay and consistent with data obtained from other cell types [145, 156]. In contrast, 
Lipofectamine 2000 was associated with significant cellular toxicity, a highly undesirable 
characteristic when delivering anti-inflammatory therapeutics. The toxicity observed in this 
study is not limited to the IB3-1 cell type  [216]. While ODN-coated nanoparticles decreased IL-
6 secretion in the presence of IL-1β stimulation, the decrease was not great enough to be 
considered significant. A lack of significance here is likely attributable to IL-6 levels that were 
near the limit of detection, which resulted in higher variability. ODN delivery with 
Lipofectamine 2000 appeared to effectively lower IL-6 levels similar to IL-8 secretion. However, 
once again, the cytotoxicity of the transfection reagent resulted in high amounts of cell death, 
decreasing the number of cells available to produce and secrete IL-6. 
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When stimulated with LPS, both IL-8 and IL-6 secretion levels were reduced at 48 hours 
when treated with ODN coated nanoparticles. Interestingly, bare PSA-TMC nanoparticles appear 
to have an anti-inflammatory effect on the IB3-1 cells, significantly reducing levels of IL-6 
secreted at 48 hours, with a similar trend seen at 24 hours. These collective results suggest that, 
in the presence of LPS, the nanoparticles have an anti-inflammatory effect on IB3-1 cells that is 
independent of the NF-κB decoy ODN. Recently, several reports have indicated that chitosan 
and quaternized chitosan can interact with and modulate the inflammatory effects of LPS in a 
variety of cell types, however the exact mechanism of this effect is not yet known [221-223]. For 
example, Ji et al. reported suppression of inflammation by chitosan via modulation of cytokines 
locally produced in periodontal ligament cells [222]. The potential for quaternized chitosan to 
modulate inflammation was further validated by the present study.  
A luciferase reporter assay was used to demonstrate that the NF-κB decoy ODN 
nanoparticles directly interfered with the NF-κB signaling pathway. As anticipated, the assay 
verified that the NF-κB decoy reduced expression of NF-κB dependent genes. The results 
obtained from the reporter assay are consistent with previous investigators who have used either 
electrophoretic mobility shift assay or other luciferase reporter assays to demonstrate the 
bioactivity of the NF-κB decoy when used in conjunction with a carrier system [206, 224-226].  
6.5 Conclusion and future work 
In general, the results obtained in the current study suggest that NF-κB decoy ODN-coated 
nanoparticles can effectively mitigate the inflammatory response for sustained periods of time 
with minimal cytotoxicity. When applied to an in vitro model of CF based on IL-1β or LPS 
activated CF epithelial cells, ODN-coated nanoparticles were able to reduce IL-6 and IL-8 
secretion at 48 hours. Although most investigators have only observed decoy ODN effects over a 
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short time period [4, 204], the results obtained here are consistent with a recent study 
demonstrating a sustained suppression of inflammation by NF-κB decoy ODN-loaded PLGA 
nanoparticles [202]. Moving forward, the IB3-1 cells will be exposed to P. aeruginosa after 
treatment with the ODN-coated nanoparticles to obtain a more comprehensive understanding of 
the anti-inflammatory activity. Furthermore, in vivo testing is required to verify that the PSA-
TMC nanoparticles are a safe, effective means of delivering nucleic acid based therapeutics to 
patients afflicted with CF.    
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7.  Modulation of the immune response of Pseudomonas 
aeruginosa infected IB3-1 lung epithelial cells using NF-κB 
decoy ODN coated polysaccharide based nanoparticles 
Abstract 
The work reported in chapter six shows encouraging data supporting the efficacy of using PSA-
TMC as a carrier system for a decoy ODN aimed at reducing airway inflammation in CF. However, 
in reality, the CF airway is an extremely complicated environment, with signaling cross-talk 
between epithelial cells and infectious pathogens, such as Pseudomonas aeruginosa, one of the 
most difficult to treat infections associated with CF. Thus, to increase the accuracy of the in vitro 
model and build a stronger case for the use of PSA-TMC-ODN as a potential CF treatment, a 
bacterial/mammalian co-culture was successfully developed. Upon method development for co-
culture creation, the model was used to conduct similar efficacy experiments as described in the 
previous chapter. However, unlike the previous chapter, an in depth analysis of inflammatory 
cytokine gene expression as well as protein secretion is reported and discussed in this chapter, also 
using slightly different time points than previously investigated. In general, in a more complex, 
physiologically relevant model and early infection time points of one and four hours, PSA-TMC-
ODN significantly reduced IL-6 and IL-8 protein secretion, while ODN administered alone only 
led to non-significant decreases. This data, combined with previous studies provides a strong 
foundation for the use of PSA-TMC-ODN as a CF treatment, and provides a transition study from 
initial in vitro efficacy testing toward the next step, in vivo safety and efficacy testing.  
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7.1 Introduction 
 Cystic fibrosis (CF) is an inherited, autosomal recessive disorder hallmarked by a 
mutation in the gene encoding the cystic fibrosis transmembrane conductance regulatory protein 
(CFTR). The CFTR protein is involved in regulating chloride ion transport in epithelial 
membranes[227]. The defective protein affects many organs through production and buildup of 
heavy mucus; however, chronic lung disease as a response to chronic infection and inflammation 
presents the greatest risk of morbidity [195, 196]. In CF patients, chronic lung infections of 
opportunistic pathogens, including Pseudomonas aeruginosa, are a major contribution to 
increased morbidity and mortality. P. aeruginosa infections are difficult to treat, as this pathogen 
is associated with resistance to many antibiotic treatments, attributed in part to the ability of this 
organism to form biofilms, supplementing the viscous mucus already produced by the host [227].  
Currently, conflicting reports exist as to whether infection causes inflammation, or innate 
inflammation increases the opportunity for infection, as detailed in a recent review by Dhooghe 
[228]. Regardless of the cause, excessive inflammation in CF is an undisputed aspect of 
pathology, with chronic bacterial infection being the leading cause of a perpetuated 
inflammatory response. Typically, an increased immune response would serve to eradicate an 
infection; however, in the CF lung, the initial immune response is not adequate, resulting in a 
chronic inflammation response [228]. Persistent inflammation leads to tissue damage, 
complicating treatment and contributing to increased morbidity and mortality rates.  
 Transcription factor nuclear factor kappa B (NF-κB) is known to play a major role in a 
variety of cellular processes, including regulation of the immune response. NF-κB is known to 
transcriptionally regulate the production of a variety of inflammatory mediators, including 
interleukin-8 (IL-8), interleukin-6 (IL-6), and granulocyte-macrophage colony stimulating factor 
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(GMCSF), cytokines directly involved in the immune response in CF [197, 229]. IL-6 stimulates 
B cells, leading to increased antibody production, while IL-8 recruits neutrophils to the infected 
area [198-200]. GMCSF is a pleiotropic cytokine involved in activating granulocytes and 
monocytes, increasing the immune cell presence and enhancing cytokine production [230]. 
Interaction of P. aeruginosa components with host cells, particularly through binding of toll like 
receptor four (TLR-4), leads to activation of the NF-kB pathway and subsequent up-regulation of 
pro-inflammatory proteins [231]. Fig. 30 illustrates the complex signaling and physical 
interactions of P. aeruginosa and the CF lung epithelium. 
Fig. 30 -Image portraying the complexities of signaling between bacterial and 
mammalian cells. Specifically, we are interested in the p50/p65 complex of NF-κB. 
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 NF-κB transcription factor decoys (ODNs) have been proposed previously as a means to 
limit NF-κB activation in CF lung epithelia [203]. While several reports have shown promising 
in vitro and in vivo studies, limited clinical success has been seen when translating ODN 
therapeutics to clinical applications [4, 204-207]. ODN based therapeutics have two major 
drawbacks: (1) a negative charge that limits cellular penetrability and (2) an extreme 
susceptibility to enzymatic degradation in physiological environments [119]. To improve 
delivery and increase stability, a variety of methods have been proposed and tested. Viral vectors 
have been considered the gold standard for DNA delivery, however, these delivery vehicles are 
often associated with toxicity when administered repeatedly [100, 101]. Non-viral delivery 
systems, including lipoplexes, polyplexes, and hybrid lipid-polymer systems have been 
developed as alternatives [232]. However, these systems all have difficulty evading the RES 
system, and lipid based reagents especially have tendency to accumulate in the liver, leading to 
payload degradation and reduced efficacy [104, 232].  
 Zhang et. al reported a nanoparticle system based on complexation of polysialic acid 
(PSA) with N-trimethyl chitosan (TMC) as a means of drug delivery for treating rheumatoid 
arthritis [145, 149]. PSA and TMC are polysaccharides, attractive choices for drug delivery 
applications due to inherent biodegradability, non-toxicity, and ease of modification [6]. PSA 
acts similarly to PEG and was pioneered as a drug delivery material by Gregoradis et. al,  who 
developed drug-PSA conjugates with extended circulation times. However, unlike PEG, PSA has 
no known receptors in the body and does not induce an immune response.  
 Chitosan is a material commonly used in DNA-polymer polyplex formation, and has 
been the subject of several comprehensive review articles [140, 233]. However, the positive 
surface charge of these polyplexes leads to rapid detection and elimination. Incorporating PSA 
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with a quaternized derivative of chitosan is expected to help evade RES detection, while 
maintaining the positive surface charge required for electrostatic association with ODN.   
We have adapted the PSA-TMC nanoparticle system to be used as a carrier for small 
oligonucleotides. Previously, we demonstrated the anti-inflammatory efficacy of decoy ODN’s 
delivered via PSA-TMC in a CF in vitro model in which soluble inflammatory mediators were 
used to induce inflammation [174]. In this study, we develop a mammalian-bacterial co-culture 
model, using human CF airway epithelial cells, and P. aeruginosa bacteria to model the 
pathology of the CF lung. In this complex CF in vitro model, we further demonstrate the ability 
of NF-κB decoy ODN coated PSA-TMC nanoparticles to reduce inflammatory gene expression 
and inflammatory protein secretion.  
7.2 Materials and Methods 
7.2.1 Materials 
 Polysialic acid (Coliminic acid, PSA) was obtained from Nacalai, USA, Inc. (San Diego, 
CA, USA). N-trimethyl chitosan TMC was produced via quaternization of chitosan (MW 100 
kDa- 300 kDa) purchased from Acros Organics (New Jersey, USA), as described previously by 
Sieval et al [163]. Sodium tripolyphosphate (TPP) was also obtained from Acros Organics (New 
Jersey, USA).  Pseudomonas aeruginosa bacteria (PA01 strain) was provided by the lab of Dr. 
Christopher Nomura (SUNY ESF, Syracuse, NY). A live/dead cell viability staining kit was 
purchased from Life Technologies (Grand Island, NY). An NF-κB decoy oligonucleotide (ODN) 
kit containing NF-κB decoy ODN (5’ CCT TGA AGG GAT TCC CTT CC 3’) and a scrambled 
ODN (5’ TTG CCG TAC CTG ACT TAG CC 3’) was purchased from CosmoBio (Tokyo, 
Japan). A QuantiGene mRNA expression level kit was purchased from Affymetrix (Santa Clara, 
CA) and ELISA kits were obtained from Peprotech (Rocky Hill, NJ). 
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7.2.3 Mammalian cell culture 
 The IB3-1 cell line consists cystic fibrosis lung epithelial cells, containing the CFTR 
mutation. IB3-1 cells were obtained from the GCFR at Johns Hopkins University. Cells were 
maintained in tissue culture treated flasks coated with collagen in LHC-8 media containing 5% 
FBS until confluent. Cells were grown in an incubator maintained at 37 °C and 5% CO2. 
7.2.4 Bacterial cell culture 
 Pseudomonas aeruginosa (PA01) strain was grown on LB media agar plates at 37°C for 
24 hours. At this time, 2-3 colonies were picked from the plate and grown for 24 hours in LHC-8 
media without gentamicin at 37°C with shaking at 200 RPM. Serial dilution plating was 
performed to determine bacterial concentration in CFU/mL after 24 hours of growth. 
7.2.5 Bacterial/mammalian co-culture development 
 IB3-1 cells were grown on collagen coated tissue culture plates in LHC-8 media with 5% 
FBS until confluent. To initiate a co-culture, IB3-1 cells were inoculated with PA01 at a 
concentration of approximately 105 CFU/ml in LHC-8 media without gentamicin or FBS. The 
co-culture was incubated for 1 hour at 37°C with 5% CO2. After 1 hour, the supernatant was 
removed and replaced with LHC-8 media without gentamicin, or LHC-8 media without 
gentamicin with 0.4% arginine and incubation continued for one or four hours. Arginine has 
been shown to facilitate bacterial adhesion while maintaining mammalian cell health [234]. At 
the indicated time points, live/dead staining was performed to assess mammalian cell health. 
7.2.6 Nanoparticle preparation and characterization 
 PSA-TMC nanoparticles (NP) coated with ODN (NP-ODN) were prepared as previously 
reported, detailed in chapter four. [145, 149, 174]. The supernatant was removed, and all 
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nanoparticles were resuspended in LHC-8 media to a concentration of 1 mg/ml prior to efficacy 
testing. 
 A Malvern Zetasizer NanoZS90 (Malvern Instruments, Malvern UK) was used to 
determine size, zeta potential, and polydispersity index of the nanoparticles. Samples were 
resuspended in 2.0 ml DI water, filtered through at 0.45 micron filter, and loaded into disposable 
cuvettes or capillary cells. All measurements were performed at 25°C. 
7.2.7  In vitro efficacy 
 IB3-1 cells were plated on collagen coated 24 well plates at a density of 50,000 cells per 
well. LHC-8 media containing 5% FBS was used to bring the well volume to 500 µl, and the 
cells were incubated for two days to allow generation of a confluent monolayer. Bare PSA-TMC 
nanoparticles (NP), ODN, and SCO coated nanoparticles (NPODN and NPSCO, respectively) 
were prepared as described in section 2.5. NP formulations were resuspended in LHC-8 media 
without FBS at a concentration of 1 mg/ml after centrifugation, and filtered through a 0.45 µm 
pore size filter. Lipofectamine 2000-ODN complexes were prepared according to manufacturer 
instructions. Briefly, 2.5µL Lipofectamine 2000 reagent and 500 ng decoy ODN were added to 
50 µL serum free LHC-8 media. After equilibration for 5 minutes, the components were then 
added together and incubated 15 minutes to allow for complex formation (Lipo-ODN). 500 µL 
of each of the following complexes were added to the prepared 24 well plates in duplicate: 1. 
Media alone, 2. ODN alone, 3. NPODN, 4. NP alone, 5. Lipo-ODN, 6. NPSCO, and 7. Media 
alone (unstimulated). Complexes were incubated with the cells for four hours/ After incubation, 
all complexes were removed, and replaced LHC-8 with media containing 5% FBS. 
 24 hours after initial treatment addition, a static co-culture was initiated. As described in 
section 7.2.4, PA01 bacteria was added to all wells except those corresponding to treatment 7 at 
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a concentration of 105 CFU/mL in gentamicin free LHC-8 media. After one hour incubation, 
supernatant was removed and immediately replaced with gentamicin free LHC-8 with 0.4% 
arginine. After incubation at 37°C, 5% CO2 for 1 or 4 hours, supernatant samples were collected 
and saved. Upon supernatant removal, as directed by manufacturer instructions, 500 µL of LHC-
8 media and 250 µL QuantiGene working lysis mixture was added to each well. The volume was 
mixed by pipetting up and down 10 times, and cells were incubated for 30 minutes at 55°C per 
manufacturer instructions to complete cell lysis. Upon completion of incubation, cell lysates 
were placed into microcentrifuge tubes and stored at -80°C.  
7.2.8 Quantitative analysis of inflammatory cytokine expression and secretion 
 A QuantiGene Plex 2.0 plex reagent system was used to amplify and quantify mRNA 
expression levels of GMCSF, IL-6, and IL-8. The kit was run on the Luminex 200 system, and 
all steps were carried out according to manufacturer instructions. Briefly, the reagent system 
employed the use of beads with varying degrees of fluorescence intensity, each different 
intensity representing a different analyte. The beads were coated with capture probes and 
hybridization extenders. mRNA is amplified, and labeled with a probe that binds streptavidin-
phycoerythrin (SAPE). The Luminex 200 system was then used to separate the different bead 
intensities, and quantify the amount of SAPE fluorescence associated with each bead. The SAPE 
fluorescence intensity allows for quantification of mRNA levels. Here, we looked a 5 different 
analytes, including cytokine IL-6, chemokine IL-8, and growth factor GMCSF, as well as two 
housekeeping genes, PPIB and ACTB. The housekeeping genes were used to normalized levels 
of IL-6, IL-8, and GMCSF in each sample. Samples were run in duplicate, and each experiment 
was repeated independently three times.   
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 IL-6, IL-8, and GMCSF ELISA kits were purchased from Peprotech (Rocky Hill, NJ) and 
run according to manufacturer’s instructions to quantify levels of the respective proteins in 
collected supernatant. Samples were run in duplicate, and each experiment was repeated 
independently three times. 
7.2.9 Statistical analysis 
 Protein and mRNA levels were expressed as fold changes relative to a control. The 
control was composed of pooled values to increase variance of the “divide by” control. Data are 
presented as mean ± standard deviation. To determine effect of exposure of IB31 cells to PA01 
bacteria, Students T test was used to compare inflammatory protein mRNA expression between 
groups treated with bacteria, and groups without exposure to PA01.  We have shown previously, 
unloaded NP and NP coated with a scrambled ODN sequence to not have a significant impact on 
inflammatory protein suppression[174]. To confirm, Student’s t test was performed between the 
NP and control, and NPSCO and control groups. NP and NPSCO were then combined with the 
control group to create the pooled control. Likewise, as we have shown Lipo-ODN induces 
cytotoxicity on this cell line, we elected not to include this group in statistical analysis. 
Therefore, groups of interest became the pooled control, ODN alone, and NPODN. One way 
ANOVA, followed by a Holm-Sidak test for multiple comparisons was performed to determine 
significance. All statistical testing was performed with an alpha value of 0.05. 
7.3 Results and Discussion 
7.3.1 Co-culture development 
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  A bacterial/mammalian co-culture model consisting of IB3-1 and PA01 was 
successfully generated, based on an adapted procedure reported initially by Anderson et. al 
[234].  An initial screening of a PA01 bacterial dilution series ranging from 106 CFU/mL to 102 
CFU/mL was performed. Live/dead staining showed IB3-1 cell health and the amount of bacteria 
adherence were not concentration dependent. Therefore, a bacterial concentration of 105 
CFU/mL was chosen for all subsequent co-culture testing. The impact of arginine on mammalian 
cell viability in the presence of bacteria was assessed by inoculating IB3-1 cells with PA01 for 1 
Fig. 31- After incubation with PA01 bacteria for one hour, live/dead staining was used to 
assess viability of IB3-1 cells. A, IB3-1 cells alone, -Arg, B., IB3-1 cells with PA01, - Arg, 
C., IB3-1 cells alone +Arg, D. IB3-1 cells with PA01 + Arg. 
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hour (Fig. 31) or 4 hours (Fig. 32) in gentamicin free LHC-8 media with or without 0.4% 
arginine. Arginine has been previously reported to facilitate bacterial attachment while 
maintaining mammalian cell health[234]. At one hour, the addition of arginine did not appear to 
have an effect on cell health, (Fig. 31); however, as shown in Fig. 32, the impact of arginine at 4 
hours was apparent. PAO1 exposure without arginine supplementation enhanced mammalian cell 
death and increased the characteristics associated dying cells, such as rounding.  
7.3.2 PA01 induction of cytokine expression in IB3-1 
Fig. 32- After incubation with PA01 bacteria for four hours, live/dead staining was used to 
assess viability of IB3-1 cells. A, IB3-1 cells alone, -Arg, B., IB3-1 cells with PA01, - Arg, 
C., IB3-1 cells alone +Arg, D. IB3-1 cells with PA01 + Arg. 
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 To validate the use of the PA01-IB3-1 co-culture as a mimic for the in vivo inflammatory 
environment, the induction of inflammation was confirmed by comparing levels of IL-6, IL-8, 
and GMCSF mRNA in groups of IB3-1 cells exposed to PA01 to un-infected control cells at one 
and four hours. As shown in Fig. 33, at one and four hours, levels of IL-6, IL-8, and GMCSF of 
unstimulated IB3-1 cell groups were significantly lower than those of stimulated IB3-1 cell 
groups, indicating the bacterial addition did indeed have a potent inflammatory effect on IB3-1 
cells.    
7.3.3 Preparation and characterization of ODN coated PSA-TMC nanoparticles 
 As reported previously, PSA-TMC nanoparticles alone exhibit a size of close to 100 nm 
(~115 nm) and a zeta potential of ~ 37 mV. When coated with 20 BP ODN, the size increases to 
approximately 165 nm diameter, while the zeta potential decreases to 23 mV. Although the zeta 
potential was reduced by the presence of the nucleic acids, the overall positive surface charge of 
Fig. 33- Confirmation of induction of cytokine expression by IB31 cells in response to 
incubation with PA01 at one hour (A) and four hours (B). Results are expressed as fold 
changes relative to a stimulated pooled control. * Represents significant difference (alpha 
value 0.05) between stimulated (with bacteria) and unstimulated groups, determined by 
Student’s T Test. 
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the nanoparticles is expected to facilitate increased interaction with the negatively charged cell 
membrane. Furthermore, positively charged chitosan is known to have mucoadhesive properties, 
allowing for increased retention time in the mucus of the CF lung epithelium [235].  
7.3.4 Efficacy of ODN coated PSA-TMC nanoparticles: mRNA expression 
 To further validate the use of PSA-TMC nanoparticles as ODN delivery vehicles, a co-
culture environment, established as described above, was used. The expression of three 
proinflammatory mediators by IB3-1 cells upon exposure to PA01 and administration of ODN or 
NP-ODN at 1 and 4 hour time points was assessed with a QuantiGene Assay. Relative to a 
pooled control group, a significant decrease in GMCSF was observed at one hour when the cells 
were pre-treated with NPODN, as shown in Fig. 34A. However, significant differences between 
groups were not observed at 4 hours (Fig. 34B). GMCSF has recently been shown to enhance IL-
6 production when in combination with interferon gamma (INF-γ) in CF lungs cells after P. 
aeruginosa infection [236]. In a healthy individual, this would likely serve to help eradicate the 
infection, increasing the functionality of macrophages and therefore phagocytic activity, however 
Fig. 34-Effect of ODN and NPODN treatment on GMCSF expression in IB3-1 cells in an 
IB3-1/PA01 co-culture model. mRNA levels are expressed relative to a pooled control, 
and all data are presented as mean ± standard deviation. * indicates a significant 
difference of p<0.05 relative -to the untreated control group.  
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in a CF lung, increased immune cell activity contributes to chronic inflammation and eventual 
tissue damage [237]. Thus, as observed with the ODN coated nanoparticles presented herein, 
agents that cause a reduction in GMCSF may serve as a viable treatment option for mitigation 
the long term destruction caused by inflammation.  
Fig. 35- Effect of ODN and NPODN treatment on IL-6 expression in IB3-1 cells in an IB3-
1/PA01 co-culture model. mRNA levels are expressed relative to a pooled control, and all 
data are presented as mean ± standard deviation. * indicates a significant difference of 
p<0.05 relative to the untreated control group. 
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 In contrast to GMCSF, non-significant decreases in the expression of IL-6 (Fig 35) and 
IL-8 (Fig. 36) at one hour were observed upon pre-treatment of cells with ODN-coated 
nanoparticles.  The results obtained for the expression levels of IL-6 and IL-8 were surprising, as 
we have previously seen significant decreases in these secretion of these proteins at longer time 
points.  A literature search revealed other reports of discrepancies between cytokine expression 
and secretion in in vitro models [238, 239]. These reports, combined with previously published 
data reporting significant decreases in protein secretion of IL-6 and IL-8 from IB3-1 cells when 
treated with NPODN at time points of 24 and 48 hours prompted further investigation of IL-6 
and IL-8 secretion [174].   
7.3.5 Efficacy of ODN coated PSA-TMC nanoparticles: protein secretion 
 Changes in the secretion of GMCSF, IL-6, and IL-8 byIB3-1 cells within the co-culture 
environment in response to ODN and NPODN treatment were investigated at time-points of one 
Fig. 36- Effect of ODN and NPODN treatment on IL-8 expression in IB3-1 cells in an IB3-
1/PA01 co-culture model. mRNA levels are expressed relative to a pooled control, and all 
data are presented as mean ± standard deviation. * indicates a significant difference of 
p<0.05 relative to the untreated control group. 
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and four hours. GMCSF protein levels were below the limit of detection, as expected based on 
low levels of mRNA observed, thus only the results for IL-6 and IL-8 are reported herein.  
 In regards to IL-6, at one hour, NPODN treatment significantly reduced protein secretion 
from IB3-1 cells, relative to a pooled control (Fig.37A). A similar trend was observed at 4 hours; 
however, the reduction was not significant. The observed differences between IL-6 expression 
and secretion are consistent with results reported previously for other CF models. For example, 
in a CF pancreatic model, an approximately double dose of inflammatory stimulus was required 
to induce an increase in IL-6 expression relative to what was required to induce enhanced IL-6 
secretion [239]. This suggests that secretion of inflammatory proteins, such as IL-6, may be more 
responsive to inhibitory treatments when compared to expression patterns of the same 
inflammatory proteins.  
 In regards to IL-8 secretion, at both one and four hours, protein levels were significantly 
reduced when treated with NPODN compared to both ODN alone and an untreated control (Fig. 
Fig. 37- Effect of ODN and NPODN treatment on IL-6 secretion in IB3-1 cells in an IB3-
1/PA01 co-culture model. Protein levels are expressed relative to a pooled control, and all 
data are presented as mean ± standard deviation. * indicates a significant difference of 
p<0.05 relative to the untreated control group. 
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38). Although a reduction in IL-8 secretion was observed upon treatment with ODN alone at 4 
hours, the difference was not significant. Recent work by Gambari et. al reported a decrease in 
IL-8 mRNA expression of about 25% in IB3-1 cells when treated with an anti NF-κB agent. 
However, IB3-1 cells that received the same dose of the treatment exhibited 50% decrease in 
cytokine secretion, relative to untreated controls [238]. Similar to IL-6, IL-8 secretion may be 
more easily manipulated than IL-8 expression.  
The levels of secreted IL-6 and IL-8 correspond well to previous studies showing 
reductions of these protein levels at 24 and 48 hours in response to treatment with decoy ODN 
delivered via PSA-TMC nanoparticles. We expect that the increase in decoy ODN efficacy is 
due to increased cellular uptake associated with the PSA-TMC carrier system.  
 Studies have shown that the inflammatory response in the CF lung is excessive, relative 
to levels of bacterial infection [240]. Excessive amounts of neutrophils recruited to the area by 
Fig. 38- Effect of ODN and NPODN treatment on IL-8 secretion in IB3-1 cells in an 
IB3-1/PA01 co-culture model. Protein levels are expressed relative to a pooled control, 
and all data are presented as mean ± standard deviation. * indicates a significant 
difference of p<0.05 relative to the untreated control group. †represents a significant 
difference of p<0.05 relative to the ODN treated group. 
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high IL-8 levels are so vast that they cannot be cleared by macrophages, leading to cell death and 
debris build-up. In CF lung epithelia, it has been shown that the death of neutrophils due to 
bacterial infection leads to the release of DNA, which further contributes to mucus viscosity and 
impaired mucociliary clearance [228, 240]. Therefore, the use of decoy ODN must be carefully 
regulated as to not introduce excess DNA to the environment and contribute to disease 
pathology. Due to these restrictions, the amount of ODN loaded onto the PSA-TMC 
nanoparticles was kept low. As previously reported, every one mg of PSA-TMC contains 
approximately 750 ng of ODN. This is considerably less DNA being applied in vitro than other 
researchers attempting to deliver decoy ODN’s in a CF model [241, 242]. The effective anti-
inflammatory activity by lower amounts of ODN than previously reported provide evidence that 
PSA-TMC is a safe and efficacious delivery system for nucleic acid based drugs. 
7.4 Conclusions and Future Work 
 In this study, a bacterial/mammalian co-culture in vitro model of CF was successful 
generated, and used to demonstrate that PSA-TMC can successfully deliver and enhance 
therapeutic efficacy of NF-kB decoy ODN’s in a complex CF model. Although gene expression 
was mainly unaffected at the time points examined here, IL-6 and IL-8 protein secretion proved 
to be significantly lower in groups treated with ODN coated PSA-TMC at both one and four hour 
time points. This reduction in protein secretion is in agreement with previous studies, and 
suggests that PSA-TMC nanoparticles are suitable carriers for small nucleic acid based 
therapeutics.   
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8. Summary and Future Work 
To conclude, this dissertation has featured an introduction detailing the need for an improved 
delivery system for nucleic acid based therapeutics (chapter one), followed by a chapter 
extensively describing challenges faced when designing drug delivery systems (chapter two). 
After introducing two pathologies chosen as a focus for experiments (chapter three), a 
polysaccharide based nanoparticle system with potential for carrying nucleic acid based drug was 
introduced (chapter four). Chapters  five, six, and seven contained experimental methods, results 
and conclusions of in vitro efficacy experiments using a non-cytotoxic, non-immunogenic, 
polysaccharide based nanocarrier system for delivery of nucleic acid based therapeutics; 
specifically a transcription factor decoy.  
The PSA-TMC nanoparticle system proved able to successfully incorporate transcription 
factor decoy oligonucleotides, likely via electrostatic interactions with the positively charged 
surface of the particles. Furthermore, the DMARD methotrexate was able to be incorporated into 
PSA-TMC nanoparticles as previously investigated, however this time with the addition of ODN 
coated on the surface. This illustrates potential for a dual treatment approach to controlling 
inflammation in RA patients. 
PSA-TMC nanoparticles were initially designed to enhance RA treatments, however 
preliminary studies showed a lack of efficacy and an excess of variability in cytokine secretion 
when MTX loaded PSA-TMC nanoparticles were introduced to an RA in vitro model. Based on 
studies claiming enhanced efficacy of chemotherapeutics when administered in combination with 
anti NF-κB agents, PSA-TMC loaded with MTX and decoy ODN were tested on RA in vitro 
models. Initially, a cell line model was investigated (chapter five). Upon seeing success in the 
cell line, a primary cell model was used to obtain more physiologically relevant results. While 
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the primary cells yielded slightly different cytokine secretion results than the cell line, in general, 
combining MTX therapy with a decoy ODN resulted in significant reduction of inflammatory 
cytokines in both RA models. 
Initial in vitro efficacy experiments using a simple CF model revealed using PSA-TMC as a 
delivery vehicle for an NF-κB decoy ODN resulted in significantly enhanced functionality of the 
decoy, as determined through reduction in cytokine secretion at both 24 and 48 hour time points 
(chapter six). Furthermore, the reduction in cytokine secretion was presumed to be due to a 
decrease in NF-κB activity, as determined via a luciferase reporter assay, confirming delivery 
and activity of the decoy ODN. To create a more accurate in vitro environment of a CF lung, a 
mammalian/bacterial co-culture model was generated, and also used to examine efficacy of PSA-
TMC mediated NF-κB decoy ODN delivery (chapter seven). While a co-culture model was 
successfully generated, due to cell viability constraints, the time points investigated using this 
model were shorter than the previous model where instead of bacterial infection, inflammation 
was induced using soluble inflammatory mediators. Therefore, to obtain a clear picture of what 
was happening in this model at these time points, gene expression as well as cytokine secretion 
was investigated. Unexpectedly, with the exception of GMCSF at one hour, which yielded 
significantly lower levels compared to an untreated control when treated with PSA-TMC-ODN a 
reduction in expression of inflammatory genes was not observed at one and four hours. On the 
other hand, cytokine secretion analysis revealed significant reductions of cytokine levels at both 
one and four hours in groups treated with PSA-TMC-ODN.  
In addition to providing a model for investigation of PSA-TMC-ODN efficacy in studies 
described in this thesis, the bacterial/mammalian co-culture model can be a useful tool for other 
in vitro studies. PA01 bacteria can produce different virulence factors based on different growth 
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conditions, allowing for a comprehensive study of bacterial/mammalian interactions under 
multiple bacterial phenotype conditions. In addition, future preliminary testing of drug 
candidates for CF can make use of the co-culture model.  
Future work involving the PSA-TMC-ODN in applications aimed at treating either RA, CF, 
or other inflammatory conditions first and foremost involves in vivo testing. Despite best efforts 
at mimicking disease conditions in vitro, in vivo pathologies can drastically differ from cell 
culture models. In vivo testing must be done do determine both safety and efficacy of this 
particle system. As a mouse model has been previously used by the Bader lab to investigate 
efficacy of another PSA based DMARD loaded nanocarrier system for RA treatment. The mice 
tolerated the dosing well, and showed signs of decreased disease progression after treatment with 
the DMARD loaded carriers (unpublished data). Therefore, this same type of model is a logical 
choice for further investigation of PSA-TMC loaded with both ODN and MTX. Drug delivery 
systems for nucleic therapies have been examined in CF in vivo models as well. Based on 
previous successes using the rat model, this is recommended for future studies involving PSA-
TMC-ODN and CF treatment efficacy. 
In addition to in vivo work, further studies regarding how PSA-TMC acts as a protective 
carrier for the ODN should also be conducted. A protocol for simulated enzymatic degradation 
has been established, however DNA detection was not achieved likely due to the small amounts 
and short base pair sequences attempted to be detected. Further studies will require extensive 
knowledge of DNA measuring techniques, such as advanced gel electrophoresis, PCR, and 
potentially mass spectroscopy.  
To conclude, the work described in this dissertation provides compelling evidence for the use 
of polysaccharide based nanoparticle system PSA-TMC as a nanocarrier delivery system for 
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small nucleic acids, demonstrated by the application of a transcription factor decoy ODN in 
several different in vitro models of inflammatory diseases.  
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